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1. Introduction 
Metabolic diseases such as diabetes or obesity are commonly associated with 
cardiovascular disorders. Adiponectin which is an adipose-derived protein is 
downregulated in subjects with obesity-related disorders (Diez and Iglesias 2003). 
Therefore, low levels of adiponectin result in obesity-related cardiovascular diseases, 
including ischemic heart diseases and peripheral artery diseases (Ouchi, Kihara et al. 
1999; Kumada, Kihara et al. 2003; Nakamura, Shimada et al. 2004). Previous studies 
have shown that adiponectin has beneficial effects on cardiovascular systems. The 
cardioprotective effects of adiponectin include inhibition of pro-inflammatory and 
hypertrophic responses, antioxidation effect (Shibata, Ouchi et al. 2004; Antonopoulos, 
Lee et al. 2011), angiogenic effect and antiatherosclerotic effect (Wong, Wang et al. 
2004). These effects are mainly mediated by AMP-activated protein kinase (AMPK), an 
energy sensor, which is a very important enzyme in maintaining the energy balance 
within the cells. Thus, adiponectin and AMPK could be potential therapeutic targets for 
cardiovascular diseases. 
 
1.1 Adiponectin and its receptors 
Adiponectin, which is also called adipocyte complement-related protein of 30 kDa 
(acrp30), is an adipocyte-derived protein which is abundantly present in human plasma 
ranging from 3 to 30 µg/ml (Arita, Kihara et al. 1999). Adiponectin is composed of four 
distinct domains: a C-terminal globular domain, 22 collagen repeats, a variable region 
and an amino-terminal signal peptide (Scherer, Williams et al. 1995). It structurally 
belongs to the complement 1q family and exists in the serum as low molecular weight 
(LMW), middle molecular weight (MMW) and high molecular weight (HMW) proteins 
(Waki, Yamauchi et al. 2003). The LMW form is the basic unit consisting of a 
homotrimer (90kDa). Several homotrimers can be assembled into multimeric isoforms 
through disulfide in cysteine. The LMW form is formed by cysteine in the globular 
domain, while the MMW and HMW form is formed by the cysteine in the collagen-like 
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domain (Scherer, Williams et al. 1995; Waki, Yamauchi et al. 2003). In plasma, 
adiponectin exists mainly as a full-length protein. Only a small amount of adiponectin 
may circulate as globular fragment which is most likely generated by proteolytic 
cleavage in the blood (Fruebis, Tsao et al. 2001; Waki, Yamauchi et al. 2005). The 
adiponectin globular domain is detected only as a monomer (Waki, Yamauchi et al. 
2003). It protects myocardium from ischemia/reperfusion injury by inhibiting the 
oxidative/nitrate stress in mice (Tao, Gao et al. 2007). The HMW adiponectin levels are 
selectively suppressed in obese patients with ischemic heart disease, which indicates 
that the HMW form is the most active form regarding protection against insulin 
resistance (Yamauchi, Kamon et al. 2002; Aso, Yamamoto et al. 2006; Lara-Castro, Luo 
et al. 2006; Inoue, Kotooka et al. 2007). A lower ratio of HMW to LMW adiponectin has 
been shown to reflect hypoadiponectinaemia (Catalano, Hoegh et al. 2006; Plaisance, 
Grandjean et al. 2008). Recent studies show that adiponectin is also expressed in 
cardiomyocytes which acts as a cardioprotective molecule protecting against 
myocardial ischemia/reperfusion injury (Wang, Lau et al. 2010). Adiponectin knockout 
mice show diet-induced insulin resistance (Maeda, Shimomura et al. 2002), increased 
intimal hyperplasia after acute vascular injury (Kubota, Terauchi et al. 2002), and 
impaired angiogenic responses to ischemia (Shibata, Ouchi et al. 2004). 
AdipoR1, adipoR2 (Kadowaki and Yamauchi 2005), T-cadherin (Hug, Wang et al. 2004) 
are three adiponectin receptors which have been identified so far. AdipoR1 and adipoR2 
are integral membrane proteins, in which the N-terminus is internally localized while the 
C-terminus is externally localized. AdipoR1 is originally reported as a receptor for 
globular adiponectin, whereas adipoR2 is reported as a receptor for full-length 
adiponectin (Kadowaki and Yamauchi 2005). However, they also bind with the high 
molecular weight adiponectin (Yamauchi, Kamon et al. 2003; Yamauchi, Nio et al. 2007). 
Supression of adipoR1 and of adipoR2 reduces adiponectin-induced fatty acid oxidation 
(Yamauchi, Kamon et al. 2002). Disruption of adipoR1 results in an abrogation of 
adiponectin-induced AMPK activation, whereas that of adipoR2 results in decreased 
activity of peroxisome proliferator-activated receptor alpha (PPAR-) (Yamauchi, Nio et 
al. 2007). T-cadherin is identified as an adiponectin receptor by its ability to specially 
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bind the high molecular weight adiponectin in vitro (Hug, Wang et al. 2004). It also binds 
with the hexameric adiponectin (Hug, Wang et al. 2004). Recently, it is shown that 
T-cadherin directly binds with high molecular weight adiponectin and is critical for AMPK 
phosphorylation and adiponectin-mediated cardioprotection in mice (Denzel, Scimia et 
al. 2010). 
APPL1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine 
binding domain and leucine zipper motif) binds to the N-terminus of the adiponectin 
receptors and mediates adiponectin signaling via activation of AMPK and 
mitogen-activated protein kinase (MAPK). Interestingly, it is found that APPL2, an 
isoform of APPL1, binds to the adipoR1 under basal conditions and blocks the 
interaction between adipoR1 and APPL1. Once adiponectin interacts with the adipoRs, 
APPL2 is seperated from adipoR1 and APPL1 can then bind (Wang, Xin et al. 2009). 
Activated AMPK, together with activated p38 MAPK, stimulate the glucose uptake and 
fatty acid oxidation in the heart and skeletal muscle, while activated AMPK and PPAR- 
stimulate fatty acid oxidation in the muscle and liver (Yamauchi, Kamon et al. 2001). 
The adiponectin-induced activation of PPAR- differs in muscle and liver, while PPAR- 
in muscle is activated by AMPK and MAPK via adipoR1 (Yamauchi, Kamon et al. 2003; 
Yamauchi, Kamon et al. 2003), and PPAR- in liver is activated by MAPK via adipoR2 
(Yamauchi, Nio et al. 2007).  
 
1.2 AMPK and its regulation 
AMPK is a heterotrimeric complex (Figure 1), which consists of the catalytic  subunit 
and the two regulatory subunits  and  (Hardie and Hawley 2001). There are two  
isoforms (1, 2), two  isoforms (1, 2), and three  isoforms (1, 2 and 3) 
(Thornton, Snowden et al. 1998; Cheung, Salt et al. 2000). At the  subunit, there is a 
phosphorylation site at Threonine 172, which is the activation site of AMPK (Hawley, 
Davison et al. 1996). At the  subunit, there is a glycogen binding site which targets the 
AMPK complex to intracellular glycogen (McBride, Ghilagaber et al. 2009). At the  
subunit, there is an AMP binding site, which is responsible for the AMP binding and 
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AMP-dependent AMPK activation by AMPK kinases (Cheung, Salt et al. 2000). In the 
absence of AMP, association of the autoinhibitory domain with the kinase domain blocks 
the active site cleft between the small and large lobes of the kinase domain, and 
prevents access of AMPK kinases to activating Thr172 site. 
Different compositions of AMPK complex may fulfill their different functions depending 
on the distribution of the isoforms. The 1 isoform is widely expressed in many tissues, 
while the 2 isoform is highly expressed in cardiac and skeletal muscle and partially 
exists in liver (Arad, Seidman et al. 2007). The complex 222 mainly exists in the heart 
(Arad, Seidman et al. 2007). Subcellular localization of AMPK is also an important 
determinant of cell signaling. The 1 isoform is mainly localized in the cytoplasm (2-fold 
more than in the nucleus), while the 2 isoform shows an equal distribution in the 
cytoplasm and the nucleus in the INS-1 cells (Salt, Celler et al. 1998). A starvation which 
activates AMPK has no effect on the cytoplasmic/nuclear ratio for either 1 or 2 AMPK 
(Salt, Celler et al. 1998). In Hela or HEK293 cells, AMPK is present in the cytoplasm and 
nucleus and accumulates in the nuclei under various stressful conditions (heat shock or 
oxidant exposure) (Kodiha, Rassi et al. 2007). 
 
 
Figure 1: Structure of AMPK (inactive form and active form) Modified from: Cheung et el., 
Biochemical Journal (2000) Volume 346, 659-669. 
 
So far, there are three known AMPK upstream kinases: LKB1 (Serine/threonine-protein 
kinase STK11, encoded by the Peutz-Jegher syndrome tumor suppressor gene), 
Ca2+-calmodulin-dependent kinase kinase  (CaMKK) and possibly transforming 
growth factor--activated kinase (TAK1). LKB1 is a complex enzyme consisting of two 
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additional non-catalytic subunits STRAD and MO25. It has been widely accepted as one 
of the major upstream kinases phosphorylating AMPK at T172 (Hawley, Boudeau et al. 
2003; Woods, Johnstone et al. 2003; Shaw, Kosmatka et al. 2004), and has been 
reported to be responsible for AICAR and metformin mediated AMPK activation (Woods, 
Johnstone et al. 2003; Shaw, Kosmatka et al. 2004). LKB1 has been shown to be the 
major upstream kinase of the 2 catalytic subunit of AMPK in mammalian cells (Imai, 
Inukai et al. 2006). It acts as an AMP-dependent AMPK activator (Sakamoto, McCarthy 
et al. 2005; Sanders, Grondin et al. 2007). In hearts lacking LKB1, the basal activity of 
2 AMPK is vastly reduced and not increased by ischemia or anoxia, while a significant 
basal activity of 1 AMPK is observed in these hearts and markedly induced by 
ischemia or anoxia (Sakamoto, Zarrinpashneh et al. 2006). The LKB1 deficient hearts, 
which are lacking 2 AMPK activation, display increased mTOR signaling, decreased 
energy efficiency and impaired cardiac function (Ikeda, Sato et al. 2009; Jessen, Koh et 
al. 2010). CaMKK is reported as an alternative upstream kinase of AMPK which acts 
as an AMP-independent activator of AMPK in LKB1-deficient cells. It phosphorylates 
and activates AMPK in response to increased calcium, which has been observed in 
immune cells and endothelial cells (Hawley, Pan et al. 2005; Stahmann, Woods et al. 
2006). TAK1 is found to phosphorylate and activate AMPK via LKB1 (Momcilovic, Hong 
et al. 2006; Xie, Zhang et al. 2006). 
AMPK senses any circumstance that causes energy deficit including hypoxia, ischemia, 
glucose deprivation, metabolic poisons, oxidative and hyperosmotic stress and 
starvation. A very small rise in AMP levels can induce a dramatic increase in the activity 
of AMPK (Hardie and Hawley 2001). Whenever the ratio AMP/ATP increases, AMPK is 
activated and ATP-generating pathways including fatty acid oxidation and glycolysis are 
switched on. On the other hand, in response to a rise in ATP levels, AMPK switches on 
ATP-consuming pathways including fatty acid synthesis and cholesterol synthesis 
(Carling and Hardie 1989; Corton, Gillespie et al. 1994). AMPK can also be negatively 
regulated by glycogen whenever bound to the glycogen binding site in the  subunit. In 
muscle, high glycogen content represses AMPK activity (Derave, Ai et al. 2000; 
Wojtaszewski, Jorgensen et al. 2002).  
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1.3 Physiological and pharmacological AMPK activators 
As mentioned before, AMPK activation requires phosphorylation at Threonine 172 of the 
 subunit. AMPK can be both pharmacologically and physiologically activated. There 
are many AMPK activators, in which AICAR, metformin are the most common ones. 
Metformin (Fryer, Parbu-Patel et al. 2002) is a widely used drug for type 2 diabetes, 
which belongs to the biguanides. Some studies have demonstrated that metformin 
might activate AMPK by decreasing cellular energy charge because it can act as an 
inhibitor of complex I of the respiratory chain (El-Mir, Nogueira et al. 2000). Compared to 
other anti-diabetic drugs, metformin improves cardiovascular functions and reduces 
cardiovascular risks in diabetes (Gundewar, Calvert et al. 2009). However, its use to 
activate AMPK is not recommended, because of its inhibitory effects on complex I and 
glucose phosphorylation (Guigas, Bertrand et al. 2006). 
AICAR is an adenosine analog which can be phosphorylated to form 5 
aminoimidazole-4-carboxamide-1--D-ribofuranosyl-5’-monophosphate (ZMP). ZMP 
mimics the multiple effects of AMP on AMPK, not only causing allosteric activation but 
also promoting phosphorylation and activation of the upstream kinases. It is reported that 
AICAR stimulates AMPK activity and glucose transport in skeletal muscle (Wojtaszewski, 
Jorgensen et al. 2002). AICAR also induces late pre-conditioning and protects against 
myocardial ischemia/reperfusion injury (Kristiansen, Solskov et al. 2009). However, its 
use to activate AMPK in cardiomyocytes is also not recommended, because of its poor 
metabolism in these cells (Javaux, Vincent et al. 1995) and inhibition of 
AMPK-independent mitochondrial oxidative phosphorylation (Guigas, Taleux et al. 2007) 
and glucose phosphorylation (Guigas, Bertrand et al. 2006). 
A-769662, a direct activator of AMPK, activates native rat AMPK by mimicking effects of 
AMP and inhibition of dephosphorylation, and in addition causes a phosphorylation of 
ACC (Cool, Zinker et al. 2006). It binds in part on S108 which is located in the 
carbohydrate binding domain of the  subunit and causes an allosterical activation of 
AMPK. The autophosphorylation at S108 caused by A-769662 binding protects the 
activating phosphorylation at T172 from upstream kinases (Sanders, Ali et al. 2007). It is 
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also reported recently that the activation of AMPK by A-769662 requires 1 isoform of 
AMPK (Treebak, Birk et al. 2009). Similar to other AMPK activators, A-769662 has been 
shown to possess cardioprotective potential. Mice hearts pre-treated with A-769662 
demonstrate smaller infarct sizes after ischemia/reperfusion injury (Kim, Miller et al. 
2011).  
Under physiological conditions, AMPK can also be activated by adipose tissue derived 
hormones. The adipocytokine leptin can activate 2 AMPK, resulting in fatty acid 
oxidation in skeletal muscle (Minokoshi, Kim et al. 2002). The adipocytokine adiponectin 
can phosphorylate and activate AMPK both in vivo and in vitro, followed by a stimulation 
of glucose utilization and fatty acid oxidation (Yamauchi, Kamon et al. 2002). Many 
groups have demonstrated that adiponectin has cardioprotective effects which are 
mainly mediated by AMPK (Chen, Montagnani et al. 2003; Yamauchi, Kamon et al. 
2003; Ouchi, Kobayashi et al. 2004; Shibata, Ouchi et al. 2004; Shibata, Sato et al. 
2005; Cheng, Lam et al. 2007). Adiponectin stimulates nitric oxide production in 
endothelial cells through AMPK-dependent phosphorylation of eNOS (Chen, 
Montagnani et al. 2003; Cheng, Lam et al. 2007). Adiponectin protects against 
myocardial ischemia/reperfusion injury through AMPK and cyclooxygenase (COX)-2- 
dependent mechanisms (Shibata, Sato et al. 2005). Its interaction with adipoR1 and 
adipoR2 leads to enhanced glucose uptake and fatty acid oxidation which is mediated 
by AMPK and MAPK in the heart (Yamauchi, Kamon et al. 2003). Furthermore, 
adiponectin activates AMPK and inhibits both extracellular signal regulated kinase (ERK) 
activation and the hypertrophic response to -adrenergic receptor stimulation in rat 
neonatal cardiomyocytes (Shibata, Ouchi et al. 2004).  
Other potential activators of AMPK include norepinephrine, phenylephrine, 
isoproterenol, vasopressin, migration inhibitory factor (MIF), resveratrol and ROS. (Xu, 
Zhao et al. 2007; Horman, Morel et al. 2008; Saeedi, Saran et al. 2009; Jaswal, Lund et 
al. 2010).  
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1.4 AMPK and its cellular effects 
AMPK is known as an energy sensor maintaining energy balance within the cells. As 
shown in Figure 2, it is activated in response to low ATP levels, AMPK upstream kinases 
or adipokines such as adiponectin, and results in angiogenesis, glycolysis, fatty acid 
oxidation, mitochondrial biogenesis, muscle contraction and inhibition of protein 
synthesis. Mammalian target of rapamycin (mTOR) has been shown to be inhibited by 
AMPK through TSC2 phosphorylation (Inoki, Zhu et al. 2003), which leads to the 
inhibition of p70 ribosomal protein S6 kinase (p70S6 kinase), thus inhibition of protein 
synthesis. AMPK also phosphorylates eukaryotic elongation factor-2 (eEF2) kinase, 
resulting in phosphorylation and inhibition of eEF2 (Chan, Soltys et al. 2004). Besides 
various roles in cellular and whole body metabolism as described in paragraph 
1.4.1-1.4.5, AMPK was also described to activate angiogenesis via phosphorylation of 
VEGF (Zwetsloot, Westerkamp et al. 2008) and influence MLCK in smooth muscles 
(Horman, Morel et al. 2008). 
 
 
 
Figure 2: AMPK signaling pathways (AMPK upstreams and downstream targets). 
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1.4.1 Role of AMPK in mitochondrial biogenesis 
Mitochondrial biogenesis is the process by which new mitochondria are formed in the 
cells. It is thought that higher mitochondrial copy number is protective for the cells, since 
mitochondria are key regulators of the metabolic activity of the cells (McBride, Neuspiel 
et al. 2006). Mitochondrial biogenesis results in the synthesis and assembly of 
mitochondrial components controlling mitochondrial number and determining the 
cellular energy production.  
PGC-1 is the key mitochondrial transcriptional coactivator in the cells. Deletion of 
PGC-1 leads to a general reduction of mitochondrial gene expression (Handschin, 
Chin et al. 2007). PGC-1orchestrates a constellation of transcription factors, such as 
estrogen-related receptor alpha (ERR, nuclear respiratory factor 1/2 (NRF1/2), 
peroxisome proliferator-activated receptors (PPARs) and retinoid X receptor (RXR), to 
induce mitochondrial gene expression (Canto and Auwerx 2010) (Figure 3). NRF1 and 
NRF2 activate the mitochondrial transcription factor A (Tfam) which initiates the 
transcription of the mitochondrial DNA and leads to the production of mitochondrial 
proteins (Scarpulla 1997; Reznick and Shulman 2006). ERRregulates the expression 
of genes involved in oxidative phosphorylation and mitochondrial biogenesis (Schreiber, 
Emter et al. 2004). PGC-1, interacting with the nuclear hormone receptors PPAR and 
thyroid hormone receptor, activates the transcription of mitochondrial uncoupling 
protein-1 and therefore regulates the mitochondrial uncoupled respiration and 
thermogenesis (Puigserver, Wu et al. 1998). The heterodimer, from the binding of 
PGC-1 to PPAR and RXR, is involved in the regulation of enzymes, transporters and 
proteins of fatty acid oxidation (Lehman, Barger et al. 2000). 
PGC-1 is the key downstream mediator of the effects of AMPK on mitochondrial 
biogenesis. AMPK phosphorylates PGC-1 at Thr177 and Ser538, which is required for 
the induction of PGC-1 target genes and thus also the mitochondrial biogenic 
response (Jager, Handschin et al. 2007). The deacetylase SIRT1 (silent mating type 
information regulator 2 homolog 1) deacetylates PGC-1, which enhances the activity 
of PGC-1 and its transcriptional activation that is important for skeletal muscle function 
and exercise-induced mitochondrial biogenesis (Gurd 2011; Li, Muhlfeld et al. 2011; Li, 
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Pan et al. 2011). 
Physiological and pharmacological activation of AMPK by adiponectin, AICAR and 
metformin promotes mitochondrial biogenesis via upregulation of PGC-1 (Civitarese, 
Ukropcova et al. 2006). On the contrary, muscle-specific deletions of either AMPK or 
PGC-1 lead to a generalized reduction in mitochondrial gene expression and exercise 
intolerance (Jorgensen, Wojtaszewski et al. 2005; Handschin, Chin et al. 2007). 
Dominant negative 1 AMPK (T172A) reduces the effect of metformin and AICAR on 
NRF1 and Tfam expression and mitochondrial proliferation in HUVEC (Kukidome, 
Nishikawa et al. 2006), whereas 2 AMPK deletion leads to a reduction of 
pyruvate-dependent mitochondrial respiration in heart, which may due to a decrease in 
cardiolipin content that is required for the electron transfer in complex I and III (Fry and 
Green 1981; Athea, Viollet et al. 2007). 
 
 
 
Figure 3: AMPK-mediated mitochondrial biogenesis 
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1.4.2 Role of AMPK in lipid transport and utilization 
AMPK regulates lipid metabolism including fatty acid oxidation, triglyceride hydrolysis, 
long-chain fatty acid uptake and cholesterol synthesis. Acetyl CoA carboxylase (ACC) is 
one of the direct downstream targets of AMPK, which can be phosphorylated and 
inactivated by AMPK. It controls the conversion of acetyl-CoA to malonyl-CoA, an 
inhibitor of Carnitine Palmitoyl Transferase 1 (CPT1). CPT1 is responsible for the entry 
of long-chain fatty acyl-CoA into mitochondria. Decreased ACC activity results in lower 
malonyl-CoA levels, thus causing an increase in fatty acid oxidation (Kahn, Alquier et al. 
2005). In addition, AMPK phosphorylates and activates malonyl-CoA decarboxylase 
(MCD), which promotes degradation of malonyl-CoA, thus causing an increase in fatty 
acid oxidation in heart as well (Goodwin and Taegtmeyer 1999). 
The lipoprotein lipase (LPL) catalyzes the hydrolytic cleavage of fatty acids from 
triglycerides in chylomicrons, very-low-density lipoproteins, and low-density lipoproteins. 
Its activity in coronary lumen is reported to be increased by activated AMPK (An, 
Pulinilkunnil et al. 2005). During metabolic stress, AMPK-mediated recruitment of LPL 
to the coronary lumen could represent an immediate compensatory response by the 
heart to guarantee the fatty acid supply. 
In addition to the inhibition of triglyceride synthesis in liver and muscle (Muoio, Seefeld 
et al. 1999), AMPK increases the phosphorylation of hormone-sensitive lipase (HSL) at 
Ser565 in adipocytes. HSL is responsible for the hydrolysis of triglycerides, and 
phosphorylation at Ser565 precludes its isoproterenol-induced translocation to the lipid 
droplet, a major requirement for lipolysis activation (Daval, Diot-Dupuy et al. 2005).  
AMPK signaling also regulates cellular long-chain fatty acids (LCFA) uptake through 
translocation of CD36 (fatty acid translocase), one enzyme which acts as acceptor for 
fatty acids and enhances fatty acid diffusion, from intracellular storage membranes to 
the sarcolemma in cardiomyocytes (Habets, Coumans et al. 2007). AMPK also 
phosphorylates and inactivates 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), 
leading to an inhibition of cholesterol synthesis (Henin, Vincent et al. 1995). 
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1.4.3 Role of AMPK in glucose transport and utilization 
AMPK regulates glucose metabolism by inducing glucose uptake and glycolysis and by 
inhibition of glycogen synthesis. Contraction and AICAR-induced AMPK activity plays 
an important role in the glucose uptake, which is mediated by an increased translocation 
of glucose transporter 4 (Glut4) to the cell membrane (Kurth-Kraczek, Hirshman et al. 
1999; Russell, Bergeron et al. 1999). AMPK also directly phosphorylates the Glut4 
enhancer factor (GEF) which is essential for the regulation of Glut4 expression at the 
transcriptional level (Merrill, Kurth et al. 1997). AS160 (Akt substrate of 160 kDa) inhibits 
the fusion of GLUT4-vesicles with the plasma membrane and keeps the 
GLUT4-vesicles in the cytosol (Koumanov, Richardson et al. 2011). Insulin and AMPK 
activation in skeletal muscle induces the phosphorylation of AS160, which leads to an 
inhibition of AS160 activity and Glut4 translocation (Eguez, Lee et al. 2005; Treebak, 
Glund et al. 2006). AMPK induces glycolysis by phosphorylating and activating 
phosphofructokinase-2 (PFK-2) which increases the production of fructose-2,6- 
bisphosphate (F-2,6-P2) (Marsin, Bertrand et al. 2000). Glycogen synthase (GS), which 
is the key enzyme in the regulation of glycogen synthesis in skeletal muscle, has been 
shown to be phosphorylated and inhibited by AMPK in vitro (Carling and Hardie 1989). 
Pharmacological activation of AMPK by AICAR also leads to glycogen synthase 
deactivation in vivo (Wojtaszewski, Jorgensen et al. 2002). 
 
1.4.4 Role of AMPK in cell proliferation 
Many published studies indicate that AMPK activation strongly suppresses cell 
proliferation in non-malignant cells as well as in tumor cells (Rattan, Giri et al. 2005; Du, 
Guan et al. 2008; Zhou, Huang et al. 2009). This effect may be mediated through 
multiple mechanisms including the regulation of cell cycle (Williamson, Bolster et al. 
2006) and inhibition of protein synthesis (Bolster, Crozier et al. 2002). AICAR-induced 
AMPK activation inhibits growth and proliferation of cardiac fibroblasts, which involves 
inhibitory interactions between ERK and AMPK (Du, Guan et al. 2008). 
Although most studies have shown that AMPK activation suppresses cell proliferation, 
there are also reports showing that AMPK activation by AICAR enhances angiotensin 
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II-induced cardiac fibroblasts proliferation (Hattori, Akimoto et al. 2006). Furthermore, in 
vivo administration of AICAR exacerbates myocardial hypertrophy. Another group has 
shown that AMPK activity is required for proliferation and migration in response to VEGF 
in human aortic endothelial cells (Reihill, Ewart et al. 2011). Additionally, two 
independent groups have demonstrated that AMPK null mutations result in abnormal 
cellular architecture and cell polarity (Lee, Koh et al. 2007; Mirouse, Swick et al. 2007). 
The cells appear somewhat spherical in shape, lose their epithelial organization and 
form apparent multi-layered structures.  
 
1.4.5 Role of AMPK in cell death 
Adiponectin-AMPK signaling has been found to have an anti-apoptotic effect on 
cardiomyocytes (Konishi, Haraguchi et al. 2011; Park, Youn et al. 2011). It is shown that 
the anti-apoptotic effect of adiponectin on doxorubicin-induced cardiomyopathy is 
mediated by AMPK, since the suppression of AMPK results in increased apoptosis of 
cardiomyocytes (Konishi, Haraguchi et al. 2011). Metformin and A-769662-mediated 
AMPK activation is also reported to result in anti-apoptotic effects (Gundewar, Calvert et 
al. 2009; Sasaki, Asanuma et al. 2009; Kim, Miller et al. 2011). In endothelial cells, it has 
been shown that 1 but not 2 AMPK activation promotes cell survival by increasing 
NF-B-mediated expression of the anti-apoptotic proteins Bcl-2 and Survivin (Liu, Liang 
et al. 2010). Furthermore,2 AMPK dominant negative in mice shows enhanced 
myocardial injury following ischemia/reperfusion (Wang, Gao et al. 2009). 
However, AMPK activation also displays pro-apoptotic effects. Others have reported 
that AMPK activation contributes to doxorubicin-induced cell death and apoptosis in 
H9C2 cells, which is mediated by JNK, p53 and mTORC1 (Chen, Wu et al. 2011). 
Another group shows that AMPK mediates apoptosis in response to bioenergetic stress 
through activation of the pro-apoptotic gene Bcl-2 modifying factor (Bmf) (Kilbride, 
Farrelly et al. 2010). 
Activation of AMPK results in increased expression of the antioxidant enzyme MnSOD 
and reduced hyperglycemia-induced mitochondrial ROS production (Kukidome, 
Nishikawa et al. 2006). Besides, AMPK-mediated reduction in ROS production is 
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probably also mediated via induction of the redox protein thioredoxin (Trx) (Li, Song et 
al. 2009). 
 
1.5 Cardiac effects of AMPK 
AMPK monitors cellular energy status in the heart in order to meet the enormous energy 
demand for continuous contraction of the heart. It controls multiple catabolic and 
anabolic biochemical pathways and regulates the cardiac function in both physiological 
and pathophysiological conditions. During ischemia, intrinsic AMPK activation protects 
the heart against injury through mechanisms of glucose uptake induction and 
anti-apoptosis (Russell, Li et al. 2004). AMPK activators both activate AMPK before 
ischemia and enhance the degree of ischemic AMPK activation (Kim, Miller et al. 2011). 
AMPK activation also appears to modulate the myocardial response to pressure 
overload via modulation of pathways involved in cardiac hypertrophy. This effect is 
mediated by activation of Akt (Chan, Dolinsky et al. 2008), inhibition of protein synthesis 
(mTOR signaling) (Zhang, Hu et al. 2008), inhibition of nuclear factor-B (NF-B) and 
blunting the increase in cardiac angiotensin II and endothelin (Li, Yin et al. 2007; Chan, 
Dolinsky et al. 2008). The role of AMPK activation in heart failure is displayed with 
diminishing of contractile dysfunction, apoptosis and fibrosis (Sasaki, Asanuma et al. 
2009). Furthermore, AMPK phosphorylates endothelial nitric oxide synthase (eNOS) at 
Ser633, which plays a central role in maintaining cardiovascular homeostasis by 
controlling NO bioavailability (Chen, Peng et al. 2009). AMPK-induced PGC-1 
expression and NO activation are also involved in the metformin-related improvement in 
survival and cardiac function in mice (Gundewar, Calvert et al. 2009). Furthermore, 
AMPK mediates the stimulation of adiponectin on angiogenesis by promoting cross-talk 
between AMPK and Akt signaling in endothelial cells (Ouchi, Kobayashi et al. 2004). 
Adiponectin, as a physiological AMPK activator, prevents progressive cardiac 
remodelling in pressure-overloaded condition, which is mediated by AMPK activation 
and glucose metabolism (Liao, Takashima et al. 2005). It also protects the heart from 
ischemia/reperfusion injury through mechanisms of AMPK activation and 
COX-2-dependent TNF- inhibition (Shibata, Sato et al. 2005). 
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1.6 Purpose of the study 
The purpose of this study is to dissect the cellular role of 1 and 2 AMPK in H9C2 
cardiomyoblasts. 
In the present study, the following areas are investigated: 
- Is there any difference between 1 and 2 AMPK in their mediation of 
adiponectin-induced changes in mitochondrial biogenesis and mitochondrial 
function in cardiac tissues and H9C2 cardiomyoblasts? 
- Is there any difference between 1 and 2 AMPK in their regulation of cell 
proliferation in H9C2 cardiomyoblasts? 
- Is there any difference between 1 and 2 AMPK in their effect on cell death? 
- Are there differences in cellular responses between physiological (adiponectin) 
and pharmacological (A-769662) AMPK activation in H9C2 cardiomyoblasts? 
- Which adiponectin receptor is mediating the adiponectin-induced cellular effects 
in H9C2 cardiomyoblasts? 
- Which AMPK kinase is mediating the adiponectin-induced AMPK activation in 
H9C2 cardiomyoblasts? 
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2. Materials 
2.1. Reagents 
Acetic acid Roth 
Acetyl-Coenzyme A Sigma-Aldrich Chemie GmbH 
Acrylamide Serva Electrophoresis GmbH 
Ampliqon Taq®-Polymerase and related buffer Biomol GmbH 
Annexin V Roche 
APS Merck 
Agarose Sigma-Aldrich Chemie GmbH 
Ammonium acetate Amersham Pharmacia Biotech Inc. 
Antimycin A Sigma-Aldrich Chemie GmbH 
A-769662 Abbott Laboratories 
AraA (adenine 9--D-arabinofuranoside) Sigma-Aldrich Chemie GmbH 
BCIP AppliChem 
Boric acid Roth 
Bovine serum albumin Sigma-Aldrich Chemie GmbH 
Bromphenol blue Merck, Darmstadt 
Calcium chloride Roth 
Chloroform, minimum 99% Sigma-Aldrich Chemie GmbH 
Compound C Merck 
Coenzyme Q Sigma-Aldrich Chemie GmbH 
Coomassie Brillant Blue G250 Serva Electrophoresis GmbH 
p-Coumaric acid Sigma-Aldrich Chemie GmbH 
Cytochrome c Sigma-Aldrich Chemie GmbH 
DAPI AppliChem 
5,5'-Dithiobis-(2-nitrobenzoic acid) (DTNB) Sigma-Aldrich Chemie GmbH 
2,6-Dichlorophenolindophenol (DCPIP) Sigma-Aldrich Chemie GmbH 
Decylubichinol Sigma-Aldrich Chemie GmbH 
Dithiothreitol Sigma-Aldrich Chemie GmbH 
DMF Merck 
dNTP-Mix Fermentas 
DTT Roth 
Ethanol Riedel-deHaën 
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Ethylendiamintetraacetate (EDTA) Roth 
Fructose-6-Phosphate Sigma-Aldrich Chemie GmbH 
Glucose Serva Electrophoresis GmbH 
Glycerol Roth 
Glycin Roth 
GoTaq® DNA Polymerase Promega 
G-6-PDH Sigma-Aldrich Chemie GmbH 
GelRed™ Biotium 
Hydrochloric acid Riedel-deHaën 
Hydrogen peroxide AppliChem 
HEPES Roth 
Isopropanol Fluka Chemie AG 
Luminol Sigma-Aldrich Chemie GmbH 
Lysozyme Serva Electrophoresis GmbH 
Methanol Merck 
MgCl2·6H2O Sigma-Aldrich Chemie GmbH 
M- MLV Reverse Transcriptase and 5x buffer Promega 
Nicotinamidadenindinucleotide (NADH) Sigma-Aldrich Chemie GmbH 
Nicotinamidadenin-dinucleotidphosphate 
(NADPH) 
Sigma-Aldrich Chemie GmbH 
2-(N-morpholino)-ethanesulphonic acid (MES) Sigma-Aldrich Chemie GmbH 
Oxalacetate Sigma-Aldrich Chemie GmbH 
Ponceau S Merck 
Phenazine methosulfate (PMS) Sigma-Aldrich Chemie GmbH 
Primer (diverse) Invitrogen 
Pyruvate Sigma-Aldrich Chemie GmbH 
Potassium acetate Roth 
Potassium chloride Roth 
Potassium cyanide (KCN) Sigma-Aldrich Chemie GmbH 
Restriction enzymes (diverse) Fermentas GmbH 
RNase A Roth 
RNase Out Invitrogen 
Rotenone Sigma-Aldrich Chemie GmbH 
Sodium azide Sigma-Aldrich Chemie GmbH 
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Sodium chloride Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH 
SDS ultrapure Roth 
Succinate Sigma-Aldrich Chemie GmbH 
Skim milk Milbona 
Tri-Reagent Sigma-Aldrich Chemie GmbH 
Tween 20 Sigma-Aldrich Chemie GmbH 
TEMED Fluka Chemie AG 
Tris-(Hydroxymethyl)-aminomethan Roth 
Tetracycline Hydrochloride Calbiochem 
Triton X-100 Sigma-Aldrich Chemie GmbH 
T4 DNA Ligase Invitrogen 
 
2.2. Cell culture 
CellTiter-Blue® Promega 
DMSO AppliChem 
DMEM PAA Laboratories GmbH 
FBS Biochrom AG 
Formaldehyde Roth 
Glutardialdehyde Merck 
G418 Sulphate PAA Laboratories GmbH 
Glutamate PAA Laboratories GmbH 
Lipofectamine™ RNAiMax Invitrogen 
Lipofectamine™ 2000 Invitrogen 
Na-Pyruvate PAA Laboratories GmbH 
Opti-MEM®I GIBCO™ Invitrogen Corporation 
Penicillin, Streptomycin PAA Laboratories GmbH 
PBS Tablets GIBCO™ Invitrogen Corporation 
Trypsin / EDTA PAA Laboratories GmbH 
Trypan-Blue Sigma-Aldrich Chemie GmbH 
Zeocin Invitrogen 
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3. Methods 
3.1 Animals 
Male C57BL/6J mice were obtained from Charles River Germany (Sandhofer Weg 7, 
97633 Sulzfeld). 1 and 2AMPK knockout mice were originally from Dr. Benoit Viollet’s 
group in France. Wistar rats were obtained from Janvier SAS France (CS 4105, LE 
GENEST ST ISLE, F-53941 St Berthevin Cedex). All the animals were 8 to 12 weeks 
old and housed in an air-conditioned room with a 12:12 h dark-light cycle and given 
standard diet with free access to tap water. 
 
3.2 Cell culture 
3.2.1 Isolation and culture of rat adult cardiomyocytes 
After the rat was sacrificed, the aorta was cannulated and the heart was fixed on a 
trestle, followed by perfusing with perfusion medium (110 mM NaCl, 2.5 mM KCl, 1.2 
mM KH2PO4, 1.2 mM MgSO4•7H2O, 25 mM HEPES, 11 mM glucose-monohydrate, pH 
7.4) which contains 0.4% collagenase and 250 µM CaCl2 with a speed of 1 drop/second 
for 25 min. Afterwards, the whole heart was cut once horizontally and once vertically 
with the Mclwain tissue chopper (the Mickle Laboratory Engineering co. LTD., England), 
and again several times with a scalpel. Cells were then collected in a tube with 25 ml 
perfusion medium which contains collagenase, and digested for 5 min at 37°C. 
Afterwards, cells were centrifugated at 400rpm for 1min and resuspended in perfusion 
medium in which the concentration of CaCl2 raises from 125 µM, 250 mM, 500 µM to 1 
mM. Cells were finally resuspended in 20 ml CCT medium containing 1% 
penicillin/streptomycin and plated on the dishes which were precoated with 1% FBS 
overnight. The cells were incubated with 0% CO2 and 100% humidity at 37°C for 2 h, 
and then the medium was gently changed to fresh CCT medium containing 1% 
penicillin-streptomycin, followed by different treatments. 
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3.2.2 Culture of H9C2 cardiomyoblasts and cell treatment 
H9C2 cardiomyoblasts were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 4.5 g/l glucose and 3.7 g/l Na2CO3 and supplemented with 100 U/ml 
penicillin/streptomycin, 10% fetal bovine serum (FBS), 1 mM Na-pyruvate and 4 mM 
glutamate (Biochrom AG, Berlin, Germany).  
The cells were cultured in a humidified incubator with 5% CO2 at 37°C and subcultured 
when they were 60% - 80% confluent. After aspiration of the culture medium, the cells 
were washed once with warm PBS, and incubated with 0.05% trypsin/0.02% EDTA 
solution for 5 min in the incubator. When detached from the bottom, cells were collected 
into a tube together with double amount of normal medium, followed by centrifugation at 
1500 rpm for 5 min. Afterwards the cells were resuspended in 1 ml fresh medium, 
counted under microscope with the help of trypan-blue solution and a cell counting 
chamber, and seeded on new dishes with an appropriate number. 
Cells were treated with adiponectin with a concentration of 4 µg/ml, AraA with a 
concentration of 500 µM, compound C 10 µM, A-769662 10 µM, H2O2 75 µM for 
different time periods. 
 
3.2.3 Isolation of recombinant human adiponectin 
Stable HEK293 cells with an overexpression of HA-tagged human adiponectin were 
provided by H. Staiger from University of Tübingen, Germany. Cells were cultured in 
complete DMEM medium containing additionally 1 mg/ml G418 (Geneticin). When the 
cells were 90-100% confluent, medium was changed to serum-free medium. And those 
serum-free medium was collected every 2-3 days for 2-3 times. HA-tagged adiponectin 
was purified from the medium by means of the µMACS Epitope Tag Protein Isolation Kit 
(Miltenyi Biotec) according to the manufacturer’s manual. Finally, purified recombinant 
adiponectin was quantified by the BCA Protein Assay Kit (Pierce, Rockfort, USA). The 
quality of the recombinant protein was controlled by Western blot. 
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3.2.4 Transfection in H9C2 cardiomyoblasts 
For transfection in H9C2 cardiomyoblasts, transfection conditions including cell density, 
amount of transfection reagent, DNA/siRNA concentration, incubation time for forming 
liposome-DNA/siRNA complexes, and the incubation time of complexes with cells were 
always first optimized. The transfection time varied from 24 to 72 h. For DNA plasmid 
transfection into H9C2 cardiomyoblasts, Lipofectamine 2000 Reagent was used. And 
for RNAi oligonucleotide transfection, Lipofectamine RNAiMax was used according to 
the instructions of the manufacturer (Invitrogen). 
 
3.2.5 Generation of the inducible stable H9C2 cell lines 
H9C2 cardiomyoblasts were co-transfected with pcDNA 6/TR for an overexpression of 
the Tet-repressor and one of the inducible shRNA plasmids (pENTR H1/TO, pENTR 
H1/TO 1 AMPK shRNA or pENTR H1/TO 2 AMPK shRNA) with a Tet-on/Tet-off 
system. Plasmids were designed and produced according to the manual of 
BLOCK-iT™-Inducible H1 RNAi Entry Vector Kits (Invitrogen). This transfection followed 
the same protocol as for transient transfection. On the next day, cells were trypsinized, 
counted, and put into the first row of a 96 well plate with an appropriate number. These 
cells were further diluted 1:2 serially in the same 96 well plate until one single cell was 
obtained in a single well. In the mean time, medium containing 1 mg/ml G418 and 250 
µg/ml zeocin was used for further culture. Finally, a series of single cells became a 
series of stable cell lines. Knock down of AMPK in those stable H9C2 cell lines was 
achieved by incubating with 10 µg/ml tetracycline for 96 h, and the knock-down 
efficiency of each stable cell line was inspected by Western blot. The most efficient ones 
were used for further studies. 
 
3.2.6 BrdU-labling 
H9C2 cardiomyoblasts were seeded on 10 mm glass cover slips within 35 mm dishes 
the day before, and transfected with siRNAs for 48 h. Afterwards, cells were incubated 
with 10 µM bromodeoxyuridine (BrdU) in medium for 2 h and fixed with 4% 
 22 
paraformaldehyde for 10 min at RT, followed by permeablization with 0.1% triton in PBS 
for 10min at RT and denaturation with 1 N HCl in 0.1%triton/PBS for 30min at 37°C. 
After that, cells were blocked with 5% FBS in 0.1% triton/PBS for 30 min at RT, and 
incubated with anti-BrdU antibody (1:100; Roche) overnight. After three times washing 
with PBS for 15 min, cells were incubated with Cy3-conjugated anti-mouse antibody 
(1:1000; Sigma) for 1 h, followed by three times washing with PBS for 15 min. Cells 
were counterstained with DAPI (1:25000 in PBS) for 1 h. Finally, cells were embedded 
in Vectashield® fluorescent mounting medium (Vector Laboratories, Inc.) and analyzed 
under the fluorescence microscope (Olympus IX70).  
 
3.2.7 Annexin V staining 
H9C2 cardiomyoblasts were seeded on 10 mm glass cover slips within 35 mm dishes 
the day before. Cells were preincubated with 4 µg/ml adiponectin or 10 µM A-769662 for 
24h, and then treated with 75 µM H2O2 for another 24 h. Cells were washed once with 
warm PBS, followed by staining with Annexin V (1:50, Roche) and 1 µg/ml propidium 
iodide (PI) which were diluted in the incubation buffer (10 µM HEPES/NAOH, pH 7.4; 
140 mM NaCl; 5 mM CaCl2) by putting the cover slip on slide for 10 min. Data were 
analyzed under the fluorescence microscope (Olympus IX70).  
 
3.2.8 CellTiter-Blue® Cell Viability Assay 
CellTiter-Blue® Cell Viability Assay (Promega) is a method to detect a fluorescent signal 
which is produced by viable cells, since the viable cells can convert a redox dye 
resazurin into the fluorescent product resorufin. The fluorescent signal is proportional to 
the number of living cells. To perform this cell viability assay, H9C2 cardiomyoblasts 
were seeded on a white sterile fluorometric 96well-plate containing 100 µl medium. After 
being transfected with different siRNAs for 48 h, cells were incubated with 20 µl 
CellTiter-Blue® cell viability assay reagent at 37°C for 2 h. The fluorescence was read 
on 530Ex/590Em nm with the help of the program Magellan
™ (Tecan) and the infinite® 200 
PRO series Microplate Reader (Tecan).  
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3.2.9 Caspase-Glo® 3/7 Assay 
Caspase-Glo® 3/7 Assay (Promega) is a luminescent assay that measures caspase-3 
and -7 activities. Caspase-3/7 cleavage of the luminogenic substrate containing the 
DEVD sequence leads to a release of a substrate for luciferase (aminoluciferin), which 
results in the luciferase reaction and the production of light. The luminescent signal is 
proportional to the activity of caspase-3 and -7. To perform this assay, cells were 
seeded on a black sterile fluorometric 96well-plate containing 50 µl medium. After being 
transfected with different siRNAs for 48 h, cells were incubated with 50 µl caspase-Glo 
reagent at room temperature for 2 h. The luminescence were read with the help of the 
program Magellan™ (Tecan) and the infinite® 200 PRO series Microplate Reader 
(Tecan).  
 
3.3 RNA / DNA analysis 
3.3.1 RNA isolation from cells 
The cells were scraped with the help of cell-scraper in 1ml (for 35 mm dishes) 
TRI-Reagent® (Sigma, Taufkirchen, Germany). After incubation at room temperature for 
10 min, the lysate was incubated with 200 µl chloroform, vortexed for 15 seconds and 
incubated at room temperature for 10 min. Then the lysate was centrifugated at 14000 
rpm at 4°C for 15 min. The upper phase was transfered into a new tube and incubated 
with 500 µl isopropanol, vortexed again and incubated at room temperature for another 
10 min. Afterwards, the RNA was precipitated by centrifugation at 14000 rpm at 4°C for 
30 min, and pellet was washed twice with 75% ethanol. At last, the RNA pellet was dried 
at room temperature for 5 min, and dissolved in appropriate amount of sterile 
DEPC-water. The concentration of the RNA was double measured with the help of 
NanoDrop (Peqlab, Erlangen, Germany) with their absorbance at 260 nm and 280 nm. 
The quality of the RNA was checked with 1% (w/v) agarose gel electrophoresis. After 
isolation and measurement, the RNA was frozen at -80°C for long-term storage. 
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3.3.2 Reverse transcription (RT) 
For the reverse transcription, 500 ng RNA was diluted in 10 µl DEPC-H2O. After being 
denatured at 72°C for 3 min, RNA was added 15 µl of a master mix (Promega, Madison, 
WI, U.S.A) with the contents shown in table 1 into each sample and incubated for 30 
min at 42°C. Then the temperature was raised to 95°C for 1 min to inactivate the 
enzymes, followed by cooling to 4°C. Finally, the product was added an equal volume of 
sterile water and further used for PCR or stored at -20°C. 
 
Table 1: RT master mix content 
Substance Volume in µl 
30 µg/ml random primers 3.0 
M-MLV RT 5x buffer  5.0 
12.5 mM dNTP 1.0 
40 U/µl RNase out (ribonuclease inhibitor) 0.25 
200 U/µl reverse transcriptase  0.25 
DEPC-dH2O 5.5 
 
3.3.3 Polymerase chain reaction (PCR) 
The complementary DNA (cDNA), which was synthesized by reverse transcription, was 
further used in semi-quantitative PCR for detecting the expression of different isoforms 
of AMPK, genes related to mitochondrial biogenesis, adiponectin receptors, AMPK 
kinases and some house keeping genes. 
All PCRs were performed in 500 µl PCR tubes containing 25 µl of a mixture as shown in 
table 2. The primers that were used are shown in table 3. The PCR procedure is shown 
in table 4. 
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Table 2: Regular PCR master mix 
Substance Volume 
in µl  
Substance Volume 
in µl 
5x Green Goltaq flexi buffer  5.0 
 
10x Pfu buffer  2.5 
25 mM MgCl2 1.5 
 
100 µM dNTP mix 3.0 
100 µM dNTP mix 3.0 
 
10 pmol/µl sense primer  0.5 
10 pmol/µl sense primer  0.5 
 
10 pmol/µl anti sense primer  0.5 
10 pmol/µl anti sense 
primer  
0.5 
 
Ampliqon Taq DNA 
polymerase 
0.25 
Gotaq polymerase 0.125 
 
cDNA 2.0 
cDNA 2.0 
 
dH2O 16.25 
dH2O 12.375 
   
 
Table 3: Primer sequences used in regular PCR 
Name of 
the 
Primers 
Specificity 
of the 
Primers 
Sequence of sense primer 
 
Sequence of antisense primer 
Length of 
fragments 
(bp) 
1 AMPK 
 
rat 
5´-CCCCTATTATTTGCGTGTGC-3´ 
3´-ACTTCTGAGGGCTTTCCTTGA-5´ 
 
239 
2 AMPK 
 
rat 
5´-AGCATCGATGATGAGGTGGT-3´ 
3´-CAACGGGCTAAAGCAGTGAT-5´ 
 
247 
 
1 AMPK 
 
rat 
5´-ACCGTATTTCGATGGACAGG-3´ 
3´-CCCGTGTCCTTGTTCAAGAT-5´ 
 
421 
2 AMPK 
 
rat 
5´-ATGGGAAACACCACCAGTGA-3´ 
3´-TGGGTGGGCTTCACAGAA-5´ 
 
218 
1 AMPK 
 
rat 
5´-CAGCTCCGGAGAATGAACA-3´ 
3´-CAAGCTGGCATTTGGAGAA-5´ 
 
382 
2 AMPK 
 
rat 
5´-TTCCAGGAGGAAGAAGACTCAG-3´ 
3´-ATTCACCAAAGGCTTGAAGGT-5´ 
 
341 
3 AMPK 
 
rat 
5´-AAAGCTTCCAGATGGACGAG-3´ 
3´-AGCTCACAGTCCCAGACCTC-5´ 
 
283 
PGC-1  
 
rat 
5´-CCGAGAATTCATGGAGCAAT-3´ 
3´-GTGTGAGGAGGGTCATCGTT-5´ 
 
114 
NRF1 
 
rat 
5´-TGTGCGTTCATTTGGCTAAG-3´ 
3´-GTTAAGGGCCATGGTGACAG-5´ 
 
230 
Tfam 
 
rat 
5´-CGCCTGTCAGCCTTATCTGT-3´ 
3´-CCCATCAGCTGACTTGGAGT-5´ 
 
288 
ND1 
 
rat 
5´-ATTTATTATCGCCCCAACCC-3´ 
3´-CAGGCGGGGATTAATAGTCA-5´ 
 
354 
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ND5 
 
rat 
5´-ACCCATGCATTCTTCAAAGC-3´ 
3´-AATGCTAGGCGTTTGATTGG-5´ 
 
386 
 
NDUFB8 
 
rat 
5´-TGCGTGTGGAAGACTACAG-3´ 
3´-CAGGAAACCGGTGTAGGAGA-5´ 
 
208 
COX I 
 
rat 
5´-ACAGTAGGGGGCCTAACAGG-3´ 
3´-CACTTCTCGTTTTGATGCGA-5´ 
 
402 
COX III 
 
rat 
5´-GAACATACCAAGGCCACCAC-3´ 
3´-GAGCCGTAAATTCCGTCTGA-5´ 
 
391 
 
COX IV 
 
rat 
5´-TTGGCAAGAGAGCCATTTCT-3´ 
3´-ACTCATTGGTGCCCTTGTTC-5´ 
 
270 
adipoR1 
 
rat 
5´-CTATCGCTGAGGGCTTTGTC-3´  
3´-TGTCTGTGAAGGACCAGCAG-5´ 
 
497 
adipoR2 
 
rat 
5´-TGGGAAGTTTTGTTCCTTGG-3´ 
3´-AGAGGGCAGCTCCTGTGATA-5´ 
 
300 
LKB1 
 
rat 
5´-GAGGTTCTCCATCCGACAGA-3´ 
3´-CTGACCCACTTCCTCTTCCA-5´ 
 
259 
 
CAMKK 
 
rat 
5´-CCATCCCTGTCCTACTCACC-3´ 
3´-CCTGTCGGATCAGCTTCTTT-5´ 
 
244 
18 S 
 
rat 
5´-GTTGGTGGAGCGATTTGTCTGG-3´ 
3´-AGGGCAGGGACTTAATCAACGC-5´ 
 
351 
GAPDH 
 
rat 
5´-CATCACCATCTTCCAGGAGCG-3´ 
3´-TGACCTTGCCCACAGCCTTG-5´ 
 
442 
 
Table 4: Regular PCR procedure 
1. First denaturation 95°C 2 min. 
2. Denaturation 95°C 30 sec. 
3. Annealing gene-related 30 sec. 
4. Extension 72°C 30 sec. 
5. Final extension 72°C 2 min. 
6. Pause 4°C  
 
3.3.4 Gelelectrophoresis 
After amplification, 25 μl of each PCR product, along with a ladder with known molecular 
weight (50 bp-1 kb DNA ladder (Invitrogen, Germany)), were loaded on a 1% agarose 
gel (1% (w/v) agarose boiled in 1x TBE buffer [89 mM Tris–HCl, pH 8.0; 89 mM boric 
acid; 2.5 mM EDTA, pH 8.8]) containing GelRed™ (1:50000, Biotium). An 
electrophoresis was performed in 1x TBE buffer at 80-160 volt. Before loading on the 
gel, the PCR products were mixed with sample buffer (50% (v/v) 1x Tris-EDTA (TE) 
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buffer [10 mM Tris-HCl, pH 8.8; 1 mM EDTA, pH 8.0]; 50% (v/v) glycerol; 0.25% (w/v) 
bromophenol blue). The resulting bands were photographed and analyzed with Quantity 
One system. 
 
3.3.5 Real time PCR 
Real-time PCR and subsequent data analysis were performed using the Mx3000P 
Multiplex Quantitative PCR System (Stratagene). PCR strip tubes, optical caps, and 
Brilliant SYBRgreen Quantitative PCR-Mastermix and primer pairs were purchased 
from Invitrogen. The Plexor® qPCR System (Promega) was purchased from Promega. 
DNA amplification was performed with the thermal cycling profile shown in table 8 and 9. 
Primer sequences used are listed in table 5 and 3, and the reaction mixtures are shown 
in table 6 and 7.  
 
Table 5: Primer sequences used in Plexor real-time PCR 
Name of 
the 
Primers 
Sequence of sense primer 
 
Sequence of antisense primer 
Length 
of 
fragme
nts (bp) 
 
GAPDH 
5'-CGGGAAGCTTGTCATCAATGGAAA-3' 
5'-Texas Red-iso-dC-TGGACTCCACGACGTACTCAG-3' 
 
84 
 
ND1 
5'-CCCTACTTCTAACCTCCCTGTTCTTATG-3' 
5'-HEX-iso-dC-AGTGGTAGGAAGTTTTTTCATAGGAGG-3' 
 
100 
 
NDUFB8 
5'-CGGTTTCCTGGCTTTCATGATATTC-3' 
5'-FAM-iso-dC-CGTTCCAGGTACAGATTATTGTAAGGA-3' 
108 
 
PGC-  
5'-AAGGTCCTTTTCTCGACACAGG-3' 
5'-Cy5-iso-dC-TGCCTGGAGACCTTGATCTTGAC-3' 
71 
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Table 6: Real-time PCR master mix of Plexor system 
Substance Volume in µl 
Platinum qPCR supermix-UDG 12.5 
10 µM each sense primer 0.5 
10 µM each anti-sense primer 0.5 
2.5 µM GAPDH sense primer 0.5 
2.5 µM GAPDH anti-sense primer 0.5 
cDNA 4.0 
dH2O 4.5 
 
Table 7: Real-time master mix of SYBRgreen qPCR system 
Substance Volume in µl 
SYBRgreen supermix 12.5 
Sense 0.25 
Anti-sense 0.25 
ROX reference dye 0.05 
cDNA 2.0 
dH2O 9.95 
 
Table 8: Real-time PCR procedure of Plexor system 
1. Denaturation 95°C 2 min. 
2. Denaturation 95°C 5 sec. 
3. Annealing and extension 60°C 35 sec. 
4. Dissociation 60-95°C  
 
Table 9: Real-time PCR procedure of SYBRgreen qPCR system 
1. Denaturation 95°C 10 min. 
2. Denaturation 95°C 30 sec. 
3. Annealing  60°C 30 sec. 
4. Extension 72°C 30 sec. 
5. Dissociation 60-95°C  
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3.3.6 RNA interference 
RNA interference method was used for different gene knockdown in H9C2 
cardiomyoblasts. siRNA oligos (ds RNA) as well as inducible shRNA plasmids were 
transfected into the cells. Former were ordered from Qiagen which are listed in table 10. 
 
Table 10: siRNA oligos (Qiagen) for gene knock down 
Name of the Oligo Specificity of the 
oligo 
Sequence of sense strand 
Sequence of antisense strand 
1 AMPK rat 5'-GGCACCCUCAUAUAAUCAATT-3' 
5'-UUGAUUAUAUGAGGGUGCCTG-3' 
2 AMPK rat 5'-GGCCAUAAAGUGGCAGUUATT-3' 
5'-UAACUGCCACUUUAUGGCCTG-3' 
adipoR1 rat 5'-GGCUCUAUUACUCCUUCUATT-3' 
5'-UAGAAGGAGUAAUAGAGCCAG-3' 
adipoR2 rat 5'-AAAUUGGAUUACUCUGGUATT-3' 
5'-UACCAGAGUAAUCCAAUUUAG-3' 
T-cadherin rat 5'-CCACCAUUGUGAUCGAUGATT-3' 
5'-UCAUCGAUCACAAUGGUGGCT-3' 
LKB1 rat 5'-GGGCGGUCAAGAUCCUCAATT-3' 
5'-UUGAGAUCUUGACCGCCCTG-3' 
CaMKK rat 5'-GGCCCGGUUCUACUUCCAATT-3' 
5'-UUGGAAGUAGAACCGGGCCTG-3' 
 
The plasmids which can express shRNA were prepared with the help of 
BLOCK-iT™-Inducible H1 RNAi Entry Vector Kits (Invitrogen). The sequences of 
oligonuleotides of shRNA are shown in table 11. These single-stranded DNAs were later 
annealed and ligated in pENTR/H1/TO vector according to the manual of this kit. The 
annealing reaction and ligation reaction are shown in table 12. At last, it was 
transformed into chemical competent One Shot® TOP10 E. coli and cloned. Whenever 
this plasmid is co-transfected with pcDNA 6/TR into H9C2 cardiomyoblasts, 
Tet-repressor can bind on H1/TO RNAi cassette, and the expression of shRNA can be 
induced by tetracycline. 
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Table 11: Oligonucleotides for making the inducible siRNA plasmids 
Specific for 
1AMPK rat 
 
top-strand: 
CACCGCTGTGGCTCGCCCAATTATGCGAACATAATTGGGCGA
GCCACAGC 
bottom strand: 
AAAAGCTGTGGCTCGCCCAATTATGTTCGCATAATTGGGCGA
GCCACAGC 
Specific for  
2AMPK rat 
top strand: 
CACCGCTGACTTCGGACTCTCTAATCGAAATTAGAGAGTCGG
AAGTCAGC 
bottom strand: 
AAAAGCTGACTTCGGACTCTCTAATTTCGATTAGAGAGTCCG
AAGTCAGC 
 
Table 12: Annealing and ligation reaction for making the inducible siRNA plasmids 
Annealing Reaction 200 µM top strand oligo 
200 µM bottom strand oligo 
10 x Oligo annealing buffer 
DNase/RNase-free water 
10 µl 
10 µl 
4 µl 
16 µl 
Ligation Reaction 5 x ligation buffer 
pENTR/H1/TO (0.75 ng/µl) 
ds Oligo (5 nM; 1:10.000 dilution) 
DNase/RNase-free water 
T4 DNA Ligase (1 U/µl) 
2 µl 
1 µl 
2.5 µl 
4 µl 
0.5 µl 
 
3.4 Protein analysis 
3.4.1 Extraction of total proteins from cells and tissues 
For the extraction of total proteins, the cells were scraped in 80-150 µl SDS lysis buffer 
(1 M Tris-HCl, pH 7.5; 1% (v/v) Sodiumdodecylsulfate (SDS), 4 M NaCl and freshly 
added 1:200 phosphatase/protease-inhibitor-mix). Tissues were 1:20 lysed in SDS lysis 
buffer and broken with Precellys tissue homogenizer (Peqlab). Then they were 
sonicated for 10 seconds and incubated on ice for 15 min followed by centrifugation for 
20 min at 14000 rpm at 4°C. The supernatant was transferred into a new tube and the 
protein concentration was measured by the infinite® 200 PRO series Microplate Reader 
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(Tecan) with a wave length of 570 nm, using the BCA™ Protein assay kit, and bovine 
serum albumin (BSA) was used as standard (Pierce, Rockfort, USA) according to the 
manufacturer’s manual.  
 
3.4.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
For running a SDS-PAGE, 40-100 µg protein aliquots were prepared in 1x SDS loading 
buffer (6 x SDS: 0.66 g DTT; 0.4 g SDS; 6 ml glycerol; 2 ml 1.25 M Tris-HCl, pH 6.8; 0.2 
mg bromphenolblue; and 10 ml dH2O), followed by denaturation for 5 min at 95°C. The 
SDS polyacrylamide gel, whose components are shown in table 13, was prepared with 
the help of the mini-protean II cell system (Bio-Rad, Munich, Germany). The samples 
were run on the gel together with a marker (PageRuler™ Prestained Protein Ladder Plus 
SM 1811; Fermentas) at 80 volt and as soon as the bromophenol blue colour enters the 
running gel, the voltage was increased to 140 volt. 
 
Table 13: SDS polyacrylamide gels 
   Running gel Stacking gel 
Concentration 5% 10%  
Sterile water 5.80 ml 4.30 ml 2.95 ml 
40% acrylamid 1.50 ml 3.00 ml 0.50 ml 
Buffer (1.5 M Tris-HCl, pH 8.8) 4.50 ml 4.50 ml - 
Buffer (1 M Tris-HCl, pH 6.8) - - 0.50 ml 
10% SDS 120 µl 120 µl 40 µl 
10x APS 100 µl 100 µl 25 µl 
TEMED 10 µl 10 µl 5 µl 
 
3.4.3 Western blot 
Western blot is an immunological method to detect a specific protein by antibodies. 
Following the SDS-PAGE, an electroblotting was performed in a transfer buffer (table 14) 
with the help of the mini blot transfer cell-system (Bio-Rad, Munich, Germany) for 1 h at 
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120 Volt at 4°C, and the proteins were transfered from the gel to a nitrocellulose 
membrane (0.45 µM, Protran  Schleicher and Schuell Bio Science GmbH Whatman 
group, Dassel, Germany). The membrane was stained with Ponceau S solution (table 
14) afterwards and the gel can be stained with coomassie staining solution (table 14) to 
confirm the protein amount after blotting. Afterwards, the membrane was blocked with 
5% skimmed milk which was dissolved in TBS-T buffer (table 14) for 1 h. Then the 
membrane was incubated with a primary antibody (table 15) which was diluted in 2.5% 
milk containing 0.02% NaN3 overnight at 4°C. The next day, the membrane was washed 
for three times (10 min) with TBS-T buffer, and incubated with horseradish 
peroxidase-conjugated secondary antibody (table 16) which was diluted in 2.5% milk for 
1 h at room temperature. After 3 times’ washing with TBS-T buffer, the membrane was 
covered with an enhanced chemoluminescence (ECL) solution (100 mM Tris-HCl, pH 
8.5; 0.225 mM coumaric acid; 1.25 mM luminol; 0.009% (v/v) H2O2) for 1 min. Finally, 
signals were developed by means of the machine Fusion FX7 (Peqlab, Erlangen 
Germany) and analyzed by FUSION-CAPT™ Software (Peqlab, Erlangen Germany) or 
Quantity One Software (BioRad, München Germany). 
 
Table 14: Solutions used for Western blot 
10 x running buffer 
250 mM Tris 
2 M glycine 
35 mM SDS 
dest. H2O 
Transfer buffer 
25 mM Tris 
192 mM glycine 
20% (v/v) methanol 
dest. H2O 
Ponceau S solution 
0.5 g Ponceau S 
1% (v/v) acetic acid 
dest. H2O 
TBS-T 
100 mM NaCl 
10 mM Tris 
0.2% (v/v) Tween 20 
dest. H2O 
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Table 15: Primary antibodies used for western blot 
Antibodies Company Species Dilution 
AMPK Cell Signalig Technology, Inc Rabbit 1:1000 
phospho-AMPK (Thr 172) Cell Signalig Technology, Inc Rabbit 1:1000 
AMPK1 Abcam Rabbit 1:1000 
AMPK2 Abcam Rabbit 1:1000 
phospho-ACC (Ser 79) Cell Signalig Technology, Inc Rabbit 1:500 
GAPDH Cell Signalig Technology, Inc Rabbit 1:2000 
adipoR1 IBL, Japan Rabbit 1:250 
LKB1 Cell Signalig Technology, Inc Rabbit 1:1000 
Complex I (mito.) Invitrogen Mouse 1:1000 
Complex I (nucl.) Invitrogen Mouse 1:1000 
Complex IV (mito.) Invitrogen Mouse 1:1000 
Complex IV (nucl.) Cell Signalig Technology, Inc Rabbit 1:1000 
Anti-BrdU Roche Mouse 1:100 
 
Table 16: Secondary antibodies used for western blot 
Antibodies Company Dilution 
Anti-rabbit IgG HRP-linked Santa-Cruz biotechnology inc. 1:5000 
Anti-mouse IgG HRP-linked Santa-Cruz biotechnology inc. 1:5000 
Anti-mouse Cy3-conjugated Sigma 1:1000 
 
3.5 Enzyme activity measurement 
The cells were trypsinized, washed with PBS and resuspended in an appropriate 
volume of Chappel-Perry-Medium (100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 50 mM Tris 
pH 7.5) with a concentration of 20x106 cells/ml. Then they were homogenized by 
ultrasound with a frequency of 40 sec/ml. Small aliquots were made afterwards and 
stored in liquid nitrogen for further measurement.  
All the enzyme activities were double measured by the photometer (Cary 50 Scan 
UV-Visible Spectrophotometer, Varian). The volume of all the reactions was at the end 1 
ml. Before starting the reaction, all the reaction samples were incubated at 30°C for 10 
min. 
The enzyme activities can be calculated according to the formulas bellow:       
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ΔE/min = Extinction variation / minute 
Vm.  = Measurement volume [µl] 
Fd.  = Dilution factor 
ε   = Extinction coefficient 
Vs.  = Sample volume [µl] 
d  = Diameter of the cuvette 
c   = Protein concentration in mg/ml 
 
3.5.1 Mitochondrial complex I (NADH:Ubiquinone-Oxidoreductase) 
The principle of the mitochondrial enzyme activity measurement is shown in Figure 4 
below. NADH can be oxidized by NADH:Ubiquinone-Oxidoreductase. After the inhibition 
of Complex III and Complex IV, the activity of Complex I can be obtained.  
 
Figure 4: Roles of enzymes and molecules in respiratory chain (C I: complex I; C II: complex 
II; C III, complex III; C IV, complex IV; CoQ: coenzyme Q, COX: cytochrome-c-oxidase, Cyt cox: 
oxidized cytochrome c, Cyt cred: reduced cytochrome c) 
 
Reaction: 10 mM Tris/HCl-buffer, pH 7.4; 50 mM KCl; 1 mM EDTA; 4 mM KCN; 5 µg/ml 
Antimycin A; 20 µl Homogenate (1:30).  
Reference: Reaction with 10 µM Rotenone.  
Start: 60 µM CoQ und 100 µM NADH.  
Wavelength: 340 nm; ε = 6.22 mM-1 · cm-1 
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3.5.2 Mitochondrial complex I+III (NADH:Cytochrome c- Oxidoreductase ) 
Cytochrome c can be reduced by both NADH: Cytochrome-c-Oxidoreductase and 
NADH: Cytochrome-b5-Oxidoreductase. Since the second reaction can’t be inhibited, 
the enzyme activity was measured and deduced by the value of reference with an 
inhibition of Complex III by Antimycin A (5 µg/ml).  
 
Reaction: 50 mM K-Na-Phosphate buffer, pH 8.0; 0.1 mM EDTANa; 3 mM KCN; 80 µM 
Cytochrome c; 20 µl Homogenate (1:30).  
Reference: Reaction with 5 µg/ml Antimycin A and 10 µM Rotenone.  
Start: 0.2 mM NADH (daily fresh). 
Wavelength: 550 nm; ε = 19.2 mM-1 · cm-1 
 
3.5.3 Mitochondrial complex II+III (Succinate:Cytochrome-c- 
Oxidoreductase)  
Cytochrome c can also be reduced via Succinate:Cytochrome-c-Oxidoreductase. After 
the inhibition of Complex IV, the afford of substrate for Complex II, but not for Complex I, 
the activity of Complex II+III can be measured. 
 
Reaction: 50 mM Phosphate buffer, pH 7.4; 0.2 mM EDTA-Na, pH 7.4; 10 mM Succinate, 
1% (w/v) bovine serum albumin (BSA), 3 mM KCN; 20 µl Homogenate.  
Blank: Reaction without Homogenate (1:30). 
Start: 80 µM Cytochrome cox. 
Wavelength: 550 nm; ε = 19.2 mM-1 · cm-1 
 
3.5.4 Mitochondrial complex III (Ubiquinone:Cytochrome-c- 
Oxidoreductase) 
Besides, cytochrome c can be reduced by Ubiquinone:Cytochrome-c-Oxidoreductase in 
the presence of decylubichinol, whenever there is no activity of complex I and complex 
II. 
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Reaction: 50 mM Phosphate buffer, pH 8.0; 0.1 mM EDTA-Na; 0.2% (w/v) BSA; 3 mM 
NaN3; 60 µM Cytochrome cox; 5 µl Homogenate.  
Blank: Reaction without Homogenate (1:30). 
Start: 150 µM Decylubichinol. 
Wavelength: 550 nm; ε = 19.2 mM-1 · cm-1 
 
3.5.5 Cytochrome-c-Oxidase (COX) 
Reduced cytochrome-c can be oxidized by cytochrome-c-oxidase. In this case, the 
activity of COX can be easily obtained. 
 
Reaction: 60 µM Cytochrome cred; 10 mM Phosphate buffer, pH 7.0;  
Start: 15 µl Homogenate (1:30). 
Wavelength: 550 nm; ε = 19.2 mM-1 · cm-1 
 
3.5.6 Succinate-Dehydrogenase (SDH)   
Succinate dehydrogenase, which is also known as complex II, can oxidize succinate 
into fumarate. The activity of SDH can be inhibited by malonate. Phenazine 
methosulfate (PMS) and 2, 6-Dichlorophenolindophenol (DCPIP) were used as electron 
acceptors. 
 
Reaction: 50 mM Phosphate buffer, pH 7.4; 0.1 mM Na EDTA; 0.1% (w/v) BSA; 3 mM 
KCN; 10 mM Succinate; 15 µl Homogenate (1:30).  
Start: 35 µM DCPIP and 1.63 mM PMS (daily fresh).  
Wavelength: 600 nm; ε = 19.1 mM-1 · cm-1 
 
3.5.7 Citrate-synthase (CS) 
Citrate synthase catalyzes the first step in the citric acid cycle, that joins acetyl 
coenzyme A and oxaloacetate together to form the citrate. Another product coenzyme A, 
combined with 5, 5’-Dithiobis (2-nitrobenzoic acid) (DTNB), forms a coloured complex, 
CoA-DTNB, which can be photometrically measured at 412 nm.  
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Reaction: 45.5 mM Tris-buffer, pH 7.4; 0.1% (w/v) Triton; 0.1 mM DTNB (in 0.1 M Tris, 
pH 8.0, daily fresh); 0.1 mM Acetyl-CoA (daily fresh); 10 µl Homogenate (1:30). 
Start: 0.5 mM Oxalacetate (pH 6.0-7.0, daily fresh).  
Wavelength: 412 nm; ε = 13.6 mM-1 · cm-1 
 
3.6 Statistical analysis 
The results were shown as mean values ± SEM. To test for statistical differences, the 
t-test and one-way ANOVA were used with the help of the Sigma Stat software V 3.1 
(Sigma Stat Software Inc., Chicago, USA). P values < 0.05 were considered significant. 
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4. Results 
4.1 Expression of AMPK isoforms in different cell/tissue types 
Seven different isoforms of AMPK including the house keeping gene 18S rRNA were 
detected in different tissues and cell types including rat skeletal muscle, left ventricle of 
neonatal heart and adult heart, H9C2 cardiomyoblast, H9C2 cardiomyotube, neonatal 
and adult rat cardiomyocyte, as shown in Figure 5. Most of the isoforms existed in all 
cell/tissue types. In skeletal muscle, the isoforms 2, 2 and 3 had a higher expression 
than the other isoforms. The expression of the 1 isoform was higher in H9C2 
cardiomyoblasts and cardiomyotubes, while the expression of the 2 isoform was 
higher in rat adult or neonatal cardiomyocytes and rat adult or neonatal heart tissues. 
The expression of the 1 isoform was higher in adult or neonatal cardiomyocytes and 
adult or neonatal heart tissues than in H9C2 cardiomyoblasts and cardiomyotubes, 
while there was no major difference for the expression of the 2 isoform among the 
samples. The 1 isoform was mainly expressed in adult or neonatal cardiomyocytes and 
adult or neonatal heart tissues. The 2 isoform showed a higher expression in 
cardiomyocytes and heart tissues than in H9C2 cardiomyoblasts and cardiomyotubes. 
The 3 isoform showed strongest expression in fully differentiated H9C2 
cardiomyotubes, similar to rat skeletal muscle. 
 
Figure 5: mRNA expression of AMPK isoforms in different tissue/cell types. 
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4.2 AMPK activation 
4.2.1 AMPK activation by adiponectin in H9C2 cardiomyoblasts 
AMPK activation in H9C2 cardiomyoblasts was analyzed by detecting AMPK 
phosphorylation at Thr 172 and phosphorylation of ACC, a downstream target of AMPK, 
at Ser79. H9C2 cardiomyoblasts were treated with 4 µg/ml recombinant adiponectin for 
different time periods ranging from 5 min to 24 h. As shown in Figure 6A, adiponectin 
induced an AMPK phosphorylation only after 5 min to 20 min of treatment, and this 
effect disappeared in 40 min. However, another peak of AMPK phosphorylation was 
observed after 24 h (Figure 6B). On the other hand, the effect of adiponectin on ACC 
phosphorylation seemed to be very stable between 5 min up to 24 h.  
 
 
 
Figure 6: Western Blot analysis of phospho-AMPK in H9C2 cardiomyoblasts after 
adiponectin treatment. 
H9C2 cardiomyoblasts were treated with 4 µg/ml adiponectin for 5 min, 10 min, 20 min, 40 min, 
80 min (A) or 24 h (B). The phosphorylation of AMPK and ACC were detected specifically with a 
phospho-AMPK (Thr172) or phospho-ACC (Ser79) antibody. Total AMPK and total ACC were 
detected with total-AMPK or total-ACC antibody. GAPDH was used as a loading control. n=2 per 
group. 
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4.2.2 AMPK activation by adiponectin in rat adult cardiomyocytes 
AMPK activation was also analyzed in freshly isolated adult rat ventricular 
cardiomyocytes by detecting AMPK phosphorylation at Thr 172 and phosphorylation of 
ACC at Ser79. In addition, an AMPK inhibitor, adenine 9-beta-d-arabinofuranoside 
(AraA), was used to inhibit AMPK activation. Cells were preincubated with or without 
1mM AraA for 30 min and then incubated with 4 µg/ml recombinant adiponectin for 5 or 
10 min. There was a significant increase of AMPK phosphorylation, as well as the 
phosphorylation of ACC, in adult cardiomyocytes in 5 min and 10 min after adiponectin 
treatment. Both effects were abolished by AraA pretreatment (Figure 7A). Similar to the 
results obtained in H9C2 cardiomyoblasts, adiponectin treatment resulted in an 
increased phosphorylation of both AMPK and ACC in cardiomyocytes after 24 h (Figure 
7B). 
 
 
 
Figure 7: Western Blot analysis of phospho-AMPK in rat adult cardiomyocytes after 
adiponectin treatment. 
Rat adult cardiomyocytes were pretreated with 1 mM AraA for 30 min, and then treated with 4 
µg/ml adiponectin for 5 min, 10 min (A) or just 4 µg/ml adiponectin for 24 h (B). The 
phosphorylation of AMPK and ACC were detected specifically with a phospho-AMPK (Thr172) or 
phospho-ACC (Ser79) antibody. Total AMPK and total ACC were detected with total-AMPK or 
total-ACC antibody. GAPDH was used as a loading control. n=2 per group. 
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4.2.3 mRNA Expression of adiponectin receptors in adult rat 
cardiomyocytes and H9C2 cardiomyoblasts 
So far, three different adiponectin receptors adipoR1, adipoR2 and T-cadherin have 
been described in the literature. The expression of those three adiponectin receptors 
was analyzed in adult rat cardiomyocytes and H9C2 cardiomyoblasts by 
semi-quantitative PCR. As shown in Figure 8, the mRNA expression of adipoR1 was 
much higher in cardiomyocytes than in H9C2 cardiomyoblasts, while adipoR2 and 
T-cadherin were equally expressed in those two cell types. Furthermore, T-cadherin 
mRNA expression was higher in both cardiomyocytes and H9C2 cardiomyoblasts 
compared to the other two adipoRs. The mRNA expression of adipoR1 and adipoR2 
was similar in adult rat cardiomyocytes, whereas the mRNA expression of adipoR2 was 
much higher than adipoR1 mRNA expression in H9C2 cardiomyoblasts. 
 
 
 
Figure 8: Expression of adiponectin receptors in rat adult cardiomyocytes and H9C2 
cardiomyoblasts.  
mRNA expression of adipoR1, adipoR2, T-cadherin and 18S rRNA was determined by 
semi-quantitative PCR and agarose gel electrophoresis. CMC: cardiomyocyte. n=2 per group. 
 
4.2.4 Role of adiponectin receptors in adiponectin-induced AMPK 
activation 
In order to investigate the role of adiponectin receptors in adiponectin-mediated AMPK 
phosphorylation, we performed a transient knockdown of the adiponectin receptors 
(adipoR1, adipoR2 or T-cadherin) in H9C2 cardiomyoblasts. The knockdown efficiency 
of those siRNAs was determined on the mRNA level (Figure 9) and protein level (not 
shown). As shown in Figure 9, the knockdown efficiency of both adipoR1 siRNA and 
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adipoR2 siRNA was up to 80% after 48 h, and T-cadherin siRNA had a knockdown 
efficiency of 60%. Although there are similarities in sequence and structure between 
adipoR1 and adipoR2, the tested siRNAs were proved to be specific for the respective 
receptor (Figure 9). 
 
 
 
Figure 9: Knockdown of adipoR1, adipoR2 or T-cadherin in H9C2 cardiomyoblasts.  
H9C2 cardiomyoblasts were transfected with mock, adipoR1, adipoR2 or T-cadherin siRNA for 
48 h. mRNA expression of adipoR1, adipoR2, T-cadherin and 18SrRNA was determined by 
semi-quantitative PCR and agarose gel electrophoresis. n=3 per group. 
 
Therefore, H9C2 cardiomyoblasts were transfected with mock, adipoR1, adipoR2 or 
T-cadherin siRNA for 24 h and then treated with or without 4 µg/ml recombinant 
adiponectin for another 24 h. As shown in Figure 10, there was a higher basal AMPK 
phosphorylation in the control cells than in cells after adipoR1 or adipoR2 knockdown. 
However, adiponectin was able to induce a significant AMPK phosphorylation in the 
control cells as well as in the adipoRs knockdown cells. Adiponectin-induced AMPK 
phosphorylation in adipoR1 knockdown cells did not reach the same level as in the 
control cells. Although basal AMPK activation was strongly reduced, 
adiponectin-mediated AMPK phosphorylation in adipoR2 knockdown cells reached the 
same level as in the control cells. Opposite to these results, T-cadherin knockdown did 
not result in a reduction in basal AMPK phosphorylation, but adiponectin was not able to 
induce AMPK phosphorylation in T-cadherin knockdown cells. 
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Figure 10: Role of adiponectin receptors in adiponectin-induced AMPK phosphorylation 
in H9C2 cardiomyoblasts. 
H9C2 cardiomyoblasts were first transfected with mock, adipoR1 or adipoR2 siRNA for 24 h and 
then treated with or without 4 µg/ml adiponectin for another 24 h. Phosphorylation of AMPK, total 
AMPK and adipoR1 were detected with phospho-AMPK (Thr172), total-AMPK or adipoR1 
antibody. Data represents the mean ± SEM (n=3 per group). *p<0.05.  
 
4.2.5 Role of AMPK upstream kinases, LKB1 and CaMKK on 
adiponectin-induced AMPK activation 
In order to identify the role of the two AMPK upstream kinases in adiponectin-mediated 
AMPK phosphorylation, we also performed a transient knockdown of LKB1 or CaMKK 
before adiponectin treatment. The knockdown efficiency of those siRNAs was 
determined on the mRNA level (Figure 11) and protein level (not shown). As shown in 
Figure 11, the knockdown efficiency of both LKB1 siRNA and CaMKK siRNA was up to 
60% after 48 h.  
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Figure 11: Knockdown of LKB1 and CaMKK in H9C2 cardiomyoblasts.  
H9C2 cardiomyoblasts were transfected with mock, LKB1 or CaMKK siRNA for 24 h, 48 h and 
72 h. mRNA expression of LKB1, CaMKK and 18S rRNA was determined by semi-quantitative 
PCR and agarose gel electrophoresis. n=3 per group. 
 
Therefore, H9C2 cardiomyoblasts were first transfected with mock, LKB1 or CaMKK 
siRNA for 24 h, and then treated with or without 4 µg/ml recombinant adiponectin for 
another 24 h. These experiments showed a dramatically lower basal phosphorylation 
level of AMPK in those LKB1 or CaMKK knockdown cells. However, opposite to the 
results obtained after adipoR1 or adipoR2 knockdown, adiponectin could not induce 
AMPK phosphorylation in those cells (Figure 12). 
 
Figure 12: Role of AMPK upstream kinases in adiponectin-induced AMPK 
phosphorylation in H9C2 cardiomyoblasts. 
H9C2 cardiomyoblasts were first transfected with mock, LKB1 or CaMKK siRNA for 24 h and 
then treated with or without 4 µg/ml adiponectin for another 24 h. Phosphorylation of AMPK, total 
AMPK and LKB1 were detected with phospho-AMPK (Thr172), total-AMPK or LKB1 antibody. 
Data represents the mean ± SEM (n=3 per group). *p<0.05. 
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4.2.6 AMPK activation by A-769662 
A-769662 (6,7-Dihydro-4-hydroxy-3-(2'-hydroxy[1,1'-biphenyl]-4-yl)-6-oxo-thieno[2,3 
-b]pyridine-5-carbonitrile) is a small molecular which is able to directly activate AMPK. 
H9C2 cardiomyoblasts were incubated with A-769662 with different concentrations (1, 
10, 50 and 100 µM) for 3 h. AMPK activation was analyzed by detecting AMPK 
phosphorylation at Thr172 and phosphorylation of ACC at Ser79. As shown in Figure 13, 
phosphorylation of AMPK and ACC was significantly increased in a dose dependent 
manner. 
 
 
 
Figure 13: Western Blot analysis of phospho-AMPK and phospho-ACC in H9C2 
cardiomyoblasts treated with A-769662 for 3 h. 
H9C2 cardiomyoblasts were treated with A-769662 with different concentrations (1, 10, 50 or 100 
µM) for 3 h. Phosphorylation of AMPK and ACC were detected specifically with a 
phospho-AMPK (Thr172) or phospho-ACC (Ser79) antibody. Total AMPK and total ACC were 
detected with total-AMPK or total-ACC antibody. GAPDH was used as a loading control. n=3 per 
group. *p<0.05; **p<0.005. 
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4.3 Effect of AMPK activation on mitochondrial biogenesis 
In order to know if AMPK activation affects mitochondrial biogenesis, and if there’s a 
difference in time course or extent of the observed changes between physiological 
AMPK activation and pharmacological AMPK activation, two different AMPK activators 
were used in this experiment: adiponectin and A-769662. H9C2 cardiomyoblasts were 
treated either with 4 µg/ml recombinant adiponectin or 10 µM A-769662 for 12 h, 24 h or 
48 h. mRNA expression of the mitochondrial transcription factor PGC-1, NRF1, Tfam, 
and the mitochondrial OXPHOS genes ND5, NDUFB8, COX1 and COX4 were analyzed 
by PCR. As shown in Figure 14A, adiponectin treatment resulted in a strong increase in 
the mRNA expression of various genes, known to indicate mitochondrial biogenesis. 
However, the time course for this effect was quite diverse. The mRNA expression of 
genes encoding for proteins of the respiratory chain (ND5, COX4) was induced after 12 
h and declined afterwards. The mRNA expression of mitochondrial transcription factors 
NRF1 and Tfam was induced only after 48 h. PGC-1 showed a minor acute increase in 
the mRNA expression (Figure 14A), but tended to show a reduced expression after 48 h. 
The pharmacological AMPK activator, A-769662, had a similar effect as adiponectin on 
the mRNA expression of NRF1 and Tfam. Opposite to the results obtained after 
adiponectin treatment, A-769662 induced the expression of ND5 and COX4 at a later 
time point (24 h) as shown in Figure 14B.  
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Figure 14: Effect of AMPK activation by adiponectin (A) or A-769662 (B) on mitochondrial 
gene expression in H9C2 cardiomyoblasts. 
H9C2 cardiomyoblasts were treated with either 4 µg/ml adiponectin (A) or 10 µM A-769662 (B) 
for 12 h, 24 h or 48 h. The expression of different genes were analyzed by means of 
semi-quantitative PCR, and normalized with 18S rRNA. Data represents the mean ± SEM (n=3 
per group). *p<0.05; **p<0.005; ***p<0.001. 
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4.4 Adiponectin mediated mitochondrial changes 
4.4.1 Effect of adiponectin and AMPK activation on mitochondrial gene 
expression. 
The physiological AMPK activator, adiponectin, was used for the further experiments. In 
order to know if AMPK mediates adiponectin induced mitochondrial gene expression, 
H9C2 cardiomyoblasts were preincubated with the AMPK inhibitors Compound C or 
AraA for 30 min, and then treated with 4 µg/ml recombinant adiponectin for 24 h. 
Mitochondrial gene expression of complex I gene ND1 and complex IV gene COX3 
were determined by semi-quantitative PCR. Adiponectin induced the mRNA expression 
of ND1 and COX3. Neither Compound C nor AraA influenced the basal mRNA 
expression of ND1 and COX3, but both of them reduced adiponectin-mediated increase 
in the mRNA expression of ND1 and COX3. The effect of AraA on the expression of 
these genes appeared to be stronger than the effect of compound C (Figure 15), 
although the reduction in AMPK phosphorylation achieved by these inhibitors at the 
indicated concentrations was comparable (not shown). 
 
 
 
Figure 15: Effect of adiponectin and AMPK activation on mitochondrial gene expression. 
H9C2 cardiomyoblasts were pretreated with 10 µM compound C or 1 mM AraA for 30 min, and 
then treated with 4 µg/ml adiponectin for 24 h. Gene expression of ND1 and COX3 was 
determined by semi-quantitative PCR and normalized with 18S rRNA. Data represents the mean 
± SEM (n=3 per group). *p<0.05; **p<0.01; ***p<0.001. 
 
4.4.2 Effect of adiponectin and AMPK activation on mitochondrial enzyme 
activities. 
For the functional effect of adiponectin and AMPK activation on mitochondrial enzyme 
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activities, H9C2 cardiomyoblasts were preincubated with or without 1 mM AraA for 30 
min, and then treated with 4 µg/ml recombinant adiponectin for 24 h. Cell homogenates 
were used for this analysis, and the enzymes including mitochondrial Complex I, 
Complex I+III, cytochrome-c-oxidase (COX) of the respiratory chain were determined. 
All enzyme activities were related to the activity of citrate synthase in the homogenate, 
which is a marker enzyme of mitochondrial content.  
After incubation with adiponectin for 24 h, the mitochondrial enzyme activities of 
complex I+III and complex IV were increased (Figure 16). AraA-preincubation 
completely abolished this effect without influencing the basal activities of complex I+III 
and complex IV. 
 
 
 
Figure 16: Effect of adiponectin and AMPK activation on mitochondrial enzyme activities 
in H9C2 cardiomyoblasts. 
H9C2 cardiomyoblasts were pretreated with or without 1 mM AraA for 30 min, and then treated 
with or without 4 µg/ml adiponectin for 24 h. Data were shown with activities in % citrate synthase 
activity and represents the mean ± SEM (n=3 per group). *p<0.05. 
 
4.4.3 Generation of inducible stable H9C2 cell lines with knockdown of 
AMPK 
In order to know the impact of a chronic deficiency in one of the two AMPK  isoforms 
on adiponectin-induced mitochondrial gene expression and adiponectin-mediated 
changes in mitochondrial enzyme activities, we generated inducible stable H9C2 cell 
lines. These cell lines included one control cell line, one 1 AMPK knockdown cell line 
and one 2 AMPK knockdown cell line. The expression of shRNA directed against 1 or 
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2 AMPK and therefore the knockdown effect of 1 or 2 AMPK in those stable H9C2 
cell lines were initiated by tetracycline, as shown in Figure 17. Cells were incubated with 
10 µg/ml tetracycline for 24 h, 48 h or 96 h. After 96 h, the strongest knockdown effect 
was observed. The expression of 1 or 2 AMPK was not affected after tetracycline 
treatment in stable mock-transfected cells (Figure 17). 
Interestingly, in these stable cell lines, we observed an upregulation of 2 AMPK protein 
in 1 AMPK knockdown cells compared to the mock control cell line. However, there 
was no upregulation of 1 AMPK protein in 2 AMPK knockdown cells (Figure 17). 
 
 
 
Figure 17: Tetracycline-induced RNAi knockdown of 1 or 2 AMPK in H9C2 
cardiomyoblasts. 
The H9C2 cardiomyoblasts were stably co-transfected with pcDNA6/TR and pENTR/H1/TO 
mock/1/2 shRNA, and incubation with or without 10 µg/ml tetracycline for 24, 48, or 96 h. The 
expression of 1 or 2 AMPK were detected specifically with anti-1 or 2 AMPK antibody. 
GAPDH was used as a loading control. 
 
4.4.3.1 Adiponectin-induced AMPK phosphorylation in stable AMPK 
knockdown H9C2 cell lines 
Stable H9C2 cardiomyoblasts (from control cell line, 1 AMPK knockdown cell line, 2 
AMPK knockdown cell line) were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml recombinant adiponectin for another 24 h. We observed a 
significant reduction in basal AMPK phosphorylation in both AMPK knockdown cells 
compared to the control cells. Furthermore, there was no significant increase in 
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adiponectin-induced AMPK phosphorylation in both AMPK knockdown cell lines 
compared to the control cell line, as shown in Figure 18. 
 
 
 
Figure 18: Adiponectin-induced AMPK phosphorylation in stable AMPK knockdown H9C2 
cell lines. 
Stable H9C2 cardiomyoblasts were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml adiponectin for another 24 h. Protein expression of phospho-AMPK was 
detected by specific phospho-AMPK antibody (T172). GAPDH was used as a loading control. 
Data represents % of respective control and mean ± SEM (n=3 per group). **p<0.01. 
 
4.4.3.2 Impact of alpha AMPK isoforms on adiponectin-induced complex I 
expression. 
Stable H9C2 cardiomyoblasts (from control cell line, 1 AMPK knockdown cell line, 2 
AMPK knockdown cell line) were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml adiponectin for another 24 h. As shown in Figure 19A, the basal 
mRNA expression of nuclear-encoded complex I gene, NDUFB8, was significantly 
reduced in the 1 and 2 AMPK knockdown cells. The mRNA expression of NDUFB8 
was significantly increased after adiponectin treatment in the control cell line, but not in 
the 1 and 2 AMPK knockdown cell lines. Similar results were obtained for the mRNA 
 52 
expression of mitochondrial-encoded complex I gene, ND1 (Figure 19A). Similarly, the 
basal protein expression of complex I, either mitochondrial-encoded ND1 or 
nuclear-encoded NDUFB8, was significantly reduced in the 1 and 2 AMPK 
knockdown cells. Furthermore, the protein expression of ND1 and NDUFB8 was 
significantly increased after adiponectin treatment in the control cell line, but not in the 
1 and 2 AMPK knockdown cell lines (Figure 19B). 
 
Figure 19: Mitochondrial complex I expression in stable AMPK knockdown H9C2 cell lines 
after adiponectin treatment. 
Stable H9C2 cardiomyoblasts were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml adiponectin for another 24 h. A: mRNA expression of ND1 and NDUFB8 was 
detected by plexor real-time PCR. B: Protein expression of the mitochondrial-encoded complex I 
gene ND1 and nuclear-encoded complex I gene NDUFB8 was determined by western blot with 
specific anti-ND1 or anti-NDUFB8 antibodies. GAPDH was used as a loading control. Data 
represents % of respective control and mean ± SEM (n=3 per group). *p<0.05; **p<0.01; 
***p<0.001. 
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4.4.3.3 Impact of alpha AMPK isoforms on adiponectin-induced complex IV 
expression. 
Besides the mRNA and protein expression of components of complex I of the 
respiratory chain, the expression of complex IV was investigated in those stable H9C2 
cell lines with or without adiponectin treatment as well. Cells (from control cell line, 1 
AMPK knockdown cell line, 2 AMPK knockdown cell line) were incubated with 10 
µg/ml tetracycline for 72 h and then treated with 4 µg/ml recombinant adiponectin for 
another 24 h. Not like the expression of complex I genes, the basal mRNA expression of 
complex IV genes in 1 and 2 AMPK knockdown cells was similar as in the control 
cells (Figure 20A). However, the mRNA expression of mitochondrial-encoded complex 
IV gene COX I and nuclear-encoded complex IV gene COX IV was significantly 
increased after adiponectin treatment in the control cell line, but not in the AMPK 
knockdown cell lines (Figure 20A). Similarly, the basal protein expression of complex IV 
genes in 1 and 2 AMPK knockdown cells was also similar as in the control cells 
(Figure 20B). However, the protein expression of complex IV genes, either 
mitochondrial-encoded COX I or nuclear-encoded COX IV was significantly increased 
after adiponectin treatment in the control cell line, but not in the 1 and 2 AMPK 
knockdown cell lines (Figure 20B).  
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Figure 20: Mitochondrial complex IV expression in stable AMPK knockdown H9C2 cell 
lines after adiponectin treatment. 
Stable H9C2 cardiomyoblasts were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml adiponectin for another 24 h. A: mRNA expression of COX I and COX IV 
was determined by real-time PCR. B: Protein expression of mitochondrial-encoded complex IV 
and nuclear-encoded complex IV was determined by western blot with specific anti-COX I or 
anti-COX IV antibodies. GAPDH was used as a loading control. Data represents % of respective 
control and mean ± SEM (n=3 per group). *p<0.05; **p<0.01. 
 
4.4.3.4 Impact of alpha AMPK isoforms on adiponectin-mediated changes 
in mitochondrial enzyme activities. 
The enzyme activities of complex I, II, III and IV of the respiratory chain were then 
measured in those stable H9C2 cardiomyoblasts which were treated with or without 
adiponectin. Cells (from control cell line, 1 AMPK knockdown cell line, 2 AMPK 
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knockdown cell line) were incubated with 10 µg/ml tetracycline for 72 h and then treated 
with 4 µg/ml adiponectin for another 24 h. As shown in Figure 21, the basal activities of 
complex I+III and complex IV were significantly reduced in 1 and 2 AMPK knockdown 
cell lines compared to the control cell line. The enzyme activities of complex I+III and 
complex IV were increased after adiponectin treatment in the control cell line, but not in 
the 1 and 2 AMPK knockdown cell lines. We also measured the activities of complex 
I (according to Lenaz) (Lenaz, Fato et al. 1995) and complex III individually in those 
samples in addition to the combined measurement of complex I+III. There was a 
significant reduction of basal activities of complex I and complex III in 1 and 2 AMPK 
knockdown cell lines compared to the control cell line (data not shown), and we 
observed also no stimulatory effect of adiponectin in these cells. Interestingly, the basal 
enzyme activity of complex II of the respiratory chain, which contains only proteins 
encoded by the nuclear genome, was not decreased in 1 and 2 AMPK knockdown 
cells. This is a strong difference to the changes in basal enzyme activities of complex I, 
III and IV, which all contain a certain amount of mitochondrial encoded proteins. 
Furthermore, the enzyme activity of complex II was significantly increased after 
adiponectin treatment in the control cell line, but only minor changes were observed in 
1 and 2 AMPK knockdown cell lines (Figure 21). We observed no change in the 
activity of citrate synthase at basal level or after adiponectin treatment in those cell lines 
(Figure 21). Furthermore, the activities of selected glycolytic enzymes, such as lactate 
dehydrogenase (LDH) and phosphoglucose isomerase (PGI) didn’t show any change 
after AMPK knockdown or adiponectin treatment (data not shown). 
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Figure 21: Mitochondrial enzyme activities in stable AMPK knockdown H9C2 cell lines 
after adiponectin treatment. 
Stable H9C2 cardiomyoblasts were incubated with 10 µg/ml tetracycline for 72 h and then 
treated with 4 µg/ml adiponectin for another 24 h. Data represents enzyme activities normalized 
to citrate synthase activity and in % of respective control. Data were shown as mean ± SEM (n=3 
per group). *p<0.05. 
 
4.5 Analysis in alpha1 and alpha2 AMPK knockout mice 
4.5.1 Expression of alpha AMPK in alpha1 and alpha2 AMPK knockout 
mice 
Here, we compared the influence of an  AMPK isoform knockout on the expression of 
the respective other  AMPK isoform in tissues from mice with a global 1 or 2 AMPK 
knockout. As mentioned before, in our stable cell lines, we observed an upregulation of 
2 isoform in 1 AMPK knockdown cells, but no 1 isoform upregulation in 2 AMPK 
knockdown cells. However, there was no upregulation of the 2 isoform in cardiac 
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tissue of 1 AMPK knockout mice. Meanwhile, there was an upregulation of the 1 
isoform in the skeletal muscle but not in the cardiac tissue of 2 AMPK knockout mice 
(Figure 22). 
 
 
 
Figure 22: Expression of  AMPK isoforms in different AMPK knockdown or knockout 
models. 
Stable H9C2 cardiomyoblasts were incubated with 10 µg/ml tetracycline for 96 h. Protein 
expression of  AMPK isoforms was detected by specific 1 or 2-AMPK antibody. GAPDH was 
used as a loading control. KO: knockout; n=2 or 3 per group.  
 
4.5.2 Mitochondrial gene expression in alpha1 and alpha2 AMPK knockout 
mice 
In those AMPK knockout mice models, we also analyzed the protein expression of the 
mitochondrial-encoded genes of complex I (ND1) and complex IV (COX I) and the 
nuclear-encoded genes of complex I (NDUFB8) and complex IV (COX IV). We 
observed no downregulation of the mitochondrial or nuclear encoded complex I or 
complex IV genes in the cardiac tissue of 1 AMPK knockout mice. However, in 2 
AMPK knockout mice, we observed a downregulation of mitochondrial and nuclear 
encoded complex IV proteins in both skeletal muscle and cardiac tissue (Figure 23). 
Complex I did not demonstrate any significant difference between wild-type and 2 
AMPK knockout mice in skeletal muscle or cardiac tissue (Figure 23). 
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Figure 23: Expression of mitochondrial genes in AMPK knockout mice. 
Samples were from different individuals of 1 or 2 AMPK knockout mice. Protein expression of 
mitochondrial-encoded complex I, IV and nuclear-encoded complex I, IV was determined by 
specific anti-ND1, anti-COX I, anti-NDUFB8 or anti-COX IV antibodies. GAPDH was used as a 
loading control. KO: knockout; n=2 or 3 per group. 
 
4.6 Impact of AMPK isoforms on H9C2 cell proliferation. 
AMPK is not only important for mitochondrial biogenesis and function, but also 
important for cell proliferation and cell viability. So far, the impact of AMPK on 
proliferation was only shown in other cell types. In order to identify whether lack of one 
of the  AMPK isoforms influences cell proliferation differently, H9C2 cardiomyoblasts 
were transiently transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA or a 
combination of both 1 and 2 AMPK siRNA for 48 h. The knockdown efficiency of 
these AMPK siRNA oligos after 24 h and 48 h is shown in Figure 24. The cell density of 
1 AMPK knockdown cells was similar as of the control cells even after 48 h, suggesting 
no major impact of the 1 isoform on H9C2 cardiomyoblast proliferation. The 2 AMPK 
knockdown cells appeared stressed and demonstrated a strongly deteriorated 
proliferation compared to the control cells. After 48 h the confluency of both the control 
cells and the 1 AMPK knockdown cells was almost 100%, while the confluency of the 
2 AMPK knockdown cells was approximately 50%. The double  AMPK knockdown 
cells did not show a stronger suppression of proliferation compared to the single 2 
AMPK knockdown cells (Figure 24).  
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Figure 24: Impact of  AMPK isoforms on H9C2 cardiomyoblast proliferation. 
H9C2 cardiomyoblasts were transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA or 
a combination of both 1 and 2 AMPK siRNA for 48 h. Pictures from different time points (0 h, 
24 h, 48 h) are based on phase contrast microscope. 
 
H9C2 cardiomyoblasts with  AMPK knockdown were also labled with BrdU to directly 
monitor the influence of  AMPK knockdown on the cell proliferation. The 2 AMPK 
knockdown led to a significant reduction in BrdU-labling in H9C2 cardiomyoblasts. 
However, 1 AMPK knockdown also resulted in a significant reduction in BrdU-labling, 
as shown in Figure 25. Furthermore, the double  AMPK knockdown cells showed an 
even stronger reduction in BrdU-labling compared to the single 1 or 2 AMPK 
knockdown cells. 
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Figure 25: Impact of  AMPK isoforms on H9C2 cardiomyoblast proliferation. 
H9C2 cardiomyoblasts were transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA or 
a combination of both 1 and 2 AMPK siRNA for 48 h. Cells were labled with BrdU and 
counterstained with DAPI. Numbers of BrdU-labled cells and DAPI-stained cells per field were 
recorded, and percentage of BrdU-labled cells in each field was used for this analysis. Data 
represents the mean ± SEM (n=3 per group). *p<0.05;***p<0.001. 
 
4.7 Impact of AMPK activation or deletion on H9C2 cell viability 
4.7.1 Impact of alpha AMPK isoforms on H9C2 cell viability. 
AMPK has not only been described to influence cell proliferation, but also viability and 
cell death (mainly apoptotic cell death). The viability of H9C2 cardiomyoblasts with 1 or 
2 AMPK knockdown was determined with the CellTiter Blue assay, based on the ability 
of living cells to convert a redox dye into a fluorescent end product. H9C2 
cardiomyoblasts were transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA 
or a combination of both 1 and 2 AMPK siRNA for 48 h. As shown in Figure 26, cells 
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with the single 2 AMPK knockdown showed a 40% decrease in cell viability, while 
single 1 AMPK knockdown did not result in a decreased cell viability compared to the 
mock-transfected cells. A combined knockdown of 1 and 2 AMPK did not result in a 
further deterioration in cell viability compared to the single 2 AMPK knockdown cells, 
as shown in Figure 26. 
 
 
 
Figure 26: Impact of  AMPK isoforms on H9C2 cardiomyoblast viability. 
H9C2 cardiomyoblasts were transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA or 
a combination of both 1 and 2 AMPK siRNA for 48 h. The cell viability was determined by 
CellTiter Blue assay. Data represents the mean ± SEM (n=3 per group). ***p<0.001. 
 
4.7.2 Effect of AMPK activation on H2O2-induced H9C2 cell death. 
Cell viability can be reduced due to increased apoptotic or necrotic cell death, which 
was therefore analyzed in the subsequent experiments. H9C2 cardiomyoblasts were 
preincubated with 4 µg/ml recombinant adiponectin or 10 µM A-769662 for 24 h and 
then treated with 75 µM H2O2 for another 24 h. H2O2 was used as an established 
pro-oxidant stimulus known to promote cell death in various cell types. As shown in 
Figure 27, H2O2 treatment resulted in an increased number of both apoptotic Annexin 
V-positive cells and necrotic propidium iodide (PI)-positive cells. Both the physiological 
and the pharmacological AMPK activation induced by adiponectin and A-769662 did not 
influence the basal cell viability, but significantly reduced H2O2-induced cell apoptosis 
and necrosis. 
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Figure 27: Effect of adiponectin and A-769662 on H2O2-induced H9C2 cell death. 
H9C2 cardiomyoblasts were preincubated with 4 µg/ml adiponectin or 10 µM A-769662 for 24 h 
and then treated with 75 µM H2O2 for another 24 h. Cells were stained with Annexin V and 
propidium iodide (PI). Numbers of apoptotic cells (Annexin V positive), necrotic cells (PI positive), 
and total cells per field were recorded, and percentage of Annexin positive cells per total cells 
and PI positive cells per total cells in each field was used for this analysis. Data represents the 
mean ± SEM (n=5 per group). ***p<0.001. 
 
In order to further dissect the protective role of 1 and 2 AMPK, the basal activation of 
caspase 3/7 was measured after siRNA-induced knockdown of 1 AMPK, 2 AMPK or 
a combined knockdown of both  AMPK in H9C2 cardiomyoblasts. As shown in Figure 
28, cells with single 1 AMPK knockdown did not show any change in caspase 3/7 
activity, while cells with single 2 AMPK knockdown showed at least 7-fold increase in 
caspase 3/7 activity compared to the mock-transfected cells. A combined knockdown of 
1 and 2 AMPK did not result in a further induction in caspase 3/7 activity compared to 
the single 2 AMPK knockdown cells, but an almost 4-fold increase in caspase 3/7 
activity compared to the control cells. 
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Figure 28: Impact of  AMPK isoforms on caspase activities in H9C2 cardiomyoblasts. 
H9C2 cardiomyoblasts were transfected with mock siRNA, 1 AMPK siRNA, 2 AMPK siRNA or 
a combination of both 1 and 2 AMPK siRNA for 48 h. The activity of caspase 3/7 was 
determined by the caspase 3/7 Glo assay kit. Data represents the mean ± SEM (n=3 per group). 
***p<0.001. 
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5. Discussion 
The major findings of the present study are: 
1. Adiponectin-mediated AMPK activation promotes mitochondrial biogenesis and 
improves mitochondrial function in H9C2 cardiomyoblasts. Both 1 and 2 isoforms 
of AMPK are involved in mediating this effect. 
2. These adiponectin effects are mediated via both adipoR1 and adipoR2, and 
T-cadherin acts as co-receptor for adipoRs. 
3. Adiponectin-induced AMPK activation is dependent on the activation of both LKB1 
and CaMKK in H9C2 cardiomyoblasts. 
4. AMPK activation has anti-apoptotic and pro-proliferative effects in H9C2 
 
 
5.1 Regulation of AMPK and ACC by adiponectin. 
Three different phosphorylation sites on AMPK subunit have been reported. Among 
them, Thr172 is reported to be the only phosphorylation site on  subunit, which 
positively regulates AMPK activation (Hawley, Davison et al. 1996). On the other hand, 
the other two phosphorylation sites are not involved in AMPK activation (Woods, 
Vertommen et al. 2003). Ser485/491 have been reported to be autophosphorylation 
sites, inhibiting AMPK activation (Hurley, Barre et al. 2006). In the present study, only 
the phosphorylation at Thr172 was investigated. Adiponectin induced phosphorylation 
of AMPK at Thr172 in a time-dependent manner (Figure 6), which was abolished by 
AraA (Figure 7). Protein phosphatase 1 (PP1) (Woods, Vertommen et al. 2003), PP2A 
(Wu, Song et al. 2007), PP2C (Steinberg, Michell et al. 2006), which were reported to be 
involved in AMPK dephosphorylation, may participate in changes of AMPK activation 
but were not investigated in the present study. 
Adiponectin-mediated metabolic effects, such as fatty acid oxidation, are mediated via 
AMPK phosphorylation at Thr172 and activation of AMPK. Activated AMPK 
phosphorylates and thus inactivates ACC at Ser79 (Goodwin and Taegtmeyer 1999). 
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Some other phosphorylation sites on ACC, such as Ser77, Ser221, Ser1200, Ser1215, 
were also reported by some other groups. Ser77 and Ser1200 were reported to be 
associated with protein kinase A (PKA)-induced ACC phosphorylation (Ha, Daniel et al. 
1994), whereas Ser221, Ser1200, Ser1215 were reported to be associated with 
AMPK-induced ACC phosphorylation (Davies, Sim et al. 1990). In the present study, 
only the phosphorylation at Ser79 was investigated. In our study, adiponectin-induced 
ACC phosphorylation at Ser79 appeared to be more stable than AMPK phosphorylation 
(Figure 6). The protein phosphatases glutamate-activated protein phosphatase (GAPP) 
was reported to be able to dephosphorylate ACC, but was not involved in AMPK 
dephosphorylation (Gaussin, Hue et al. 1996; Kowluru, Chen et al. 2001). The stable 
phosphorylation of ACC after adiponectin treatment might therefore be related to a low 
activity of this protein phosphatase. AraA also abolished ACC phosphorylation in 
cardiomyocytes (Figure 7). However, the persistence of ACC phosphorylation after AraA 
treatment alone (Figure 7) suggests that there are other upstream kinases of ACC 
which are phosphorylating ACC at Ser79 and operating AMPK-independent. Those 
other kinases of ACC might include PKA, casein kinase I and casein kinase II as 
previously described (Witters and Bacon 1985).  
 
5.2 Adiponectin-mediated AMPK activation promotes mitochondrial 
biogenesis and mitochondrial function in H9C2 cardiomyoblasts. 
It is widely accepted that AMPK via activating transcription factors or coactivators such 
as nuclear respiratory factors (NRFs) and PGC-1 induces mitochondrial biogenesis 
(Wu, Puigserver et al. 1999; Reznick and Shulman 2006). Pharmacological activation of 
AMPK via AICAR and metformin promotes mitochondrial biogenesis via upregulation of 
PGC-1 in human umbilical vein endothelial cells (HUVEC) (Kukidome, Nishikawa et al. 
2006), and muscle-specific deletion of either AMPK or PGC-1 leads to a generalized 
reduction in mitochondrial gene expression and exercise intolerance (Jorgensen, 
Wojtaszewski et al. 2005; Leone, Lehman et al. 2005; Handschin, Chin et al. 2007). 
These studies indicate the important roles of AMPK and PGC-1 in the regulation of 
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mitochondrial biogenesis. In the present study, both the physiological (via adiponectin) 
and the pharmacological activation (via A-769662) of AMPK induced mitochondrial 
biogenesis (Figure 14), and inhibition of AMPK activity partially reversed the effect of 
adiponectin on mitochondrial biogenesis (Figure 15). This suggests that 
adiponectin/A-769662-mediated AMPK activation promotes mitochondrial biogenesis in 
H9C2 cardiomyoblasts. However, the time required to induce mitochondrial gene 
expression (particularly ND5) varies between adiponectin and A-769662 (Figure 14). 
This might be due to different mechanisms of AMPK activation and affinity to AMPK of 
these agents. Adiponectin most likely activates AMPK via adipoRs, whereas A-769662 
causes a direct allosterical activation of AMPK. It is conceivable that these differences in 
the modes of AMPK activation may influence the induction time for mitochondrial gene 
expression. Furthermore, an increase in the mRNA expression of mitochondrial 
transcriptional factors NRF1 and Tfam was observed along with AMPK activation 
(Figure 14), suggesting that NRF1 and Tfam may be involved in the effect of AMPK 
activation on mitochondrial biogenesis. Although the mRNA expression of PGC-1 was 
neither induced by adiponectin nor by A-769662 (Figure 14), a strong deacetylation of 
PGC-1, which was previously reported to result in a higher PGC-1 activity (Gurd 2011) 
was observed after adiponectin treatment in H9C2 cardiomyoblasts (data not shown). 
These findings suggest that adiponectin-induced mitochondrial biogenesis is mediated 
by AMPK-dependent PGC-1 deacetylation and NRF1/Tfam expression. 
Adiponectin, as a physiological AMPK activator, has also been shown to induce 
mitochondrial biogenesis in primary human myotubes (Civitarese, Ukropcova et al. 
2006). Deletion of adiponectin in vivo results in a lower mitochondrial content 
(Civitarese, Ukropcova et al. 2006), which suggests the necessity of adiponectin in the 
regulation of mitochondrial biogenesis in vivo. Similar findings have also been reported 
in our previous study, showing that an intact adipocytokine signaling (Leptin, 
adiponectin) is required for physical activity-induced PGC-1 deacetylation and 
mitochondrial biogenesis in mouse skeletal muscle (Li, Pan et al. 2011). Treadmill 
training induced increase in plasma adiponectin, PGC-1 deacetylation, AMPK 
phosphorylation and SIRT1 protein expression in wild type but not in ob/ob mice with 
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dysregulated adiponectin/leptin-mediated AMPK activation (Li, Pan et al. 2011). 
Likewise, it has been reported that chronic activation of AMPK by AICAR increases 
mitochondrial enzyme activities in rat skeletal muscle (Winder, Holmes et al. 2000). 
Adiponectin has been shown to induce citrate synthase activity, a marker of 
mitochondrial content, in primary human myotubes, and either knockdown of 
adiponectin receptor expression by siRNA, or pharmacological inhibition of AMPK with 
AraA blunted adiponectin-induced mitochondrial function (Civitarese, Ukropcova et al. 
2006). Accordingly, adiponectin knockout mice have also been shown to have lower 
citrate synthase activity in the skeletal muscle (Civitarese, Ukropcova et al. 2006). 
These studies indicate the important roles of adiponectin and AMPK in the regulation of 
mitochondrial biogenesis. In this present study, it was further observed that adiponectin 
could induce activities of mitochondrial complex I+III and complex IV, and 
pharmacological inhibition of AMPK completely abolished this effect in H9C2 
cardiomyoblasts (Figure 16). These data demonstrate that AMPK activation is also 
required for adiponectin-induced changes in mitochondrial function. 
 
5.3 Both alpha1 and alpha2 isoforms of AMPK are involved in 
adiponectin-mediated induction of mitochondrial biogenesis and 
mitochondrial function in H9C2 cardiomyoblasts. 
2 isoform has been proposed to be the most prevalent isoform expressed both in the 
heart and skeletal muscles (Arad, Seidman et al. 2007). Therefore, most of the previous 
studies on cardiac tissue have focused on 2 isoform. 2 AMPK deficiency has been 
shown to be associated with most of the cardiac abnormalities, such as more severe 
myocardium injury following ischemia (Russell, Li et al. 2004; Carvajal, Zarrinpashneh 
et al. 2007), more severe hypertrophy of left ventricle following pressure overload (Ping 
Zhang et al 2008), impaired cardiac cardiolipin homeostasis and cardiac mitochondrial 
dysfunction (Athea, Viollet et al. 2007). Recently, it has been shown that transient 
deletion of 2 AMPK alone or of both 1 and 2 AMPK leads to a reduction in 
adiponectin-induced mitochondrial DNA content in C2C12 myocytes (Iwabu, Yamauchi 
 68 
et al. 2010), suggesting that mainly 2 AMPK is important for adiponectin-induced 
mitochondrial biogenesis. However, little is known about the specific role of 1 isoform 
in cardiomyocytes. Therefore, the present study tried to dissect the specific role of 1 
AMPK and 2 AMPK in adiponectin-mediated changes in mitochondrial biogenesis and 
mitochondrial function. In order to identify the role of specific isoforms of AMPK in 
adiponectin-mediated mitochondrial changes in H9C2 cardiomyoblasts, 1 or 2 AMPK 
levels were modified using transient or stable and inducible siRNA techniques. Data of 
the present study showed that both1 and 2 AMPK knockdown result in a reduction in 
adiponectin-mediated mitochondrial biogenesis as well as mitochondrial enzyme 
activities in H9C2 cardiomyoblasts (Figure 19-21). Massive downregulation of complex I 
protein (Figure 19) but relatively moderate complex IV protein (Figure 20) in 1 and 2 
AMPK knockdown cells may suggest a deeper involvement of AMPK activation in 
transcription and translation of complex I than of complex IV. Reduction in the basal 
enzymatic activities of complex I and complex III but not of complex II in 1 and 2 
AMPK knockdown cells (Figure 21) may be related to differential composition and 
regulation of these components. Complex I and complex III contain a high number of 
mitochondrial-encoded proteins, but complex II contains only nuclear-encoded proteins. 
Knockout mice of 1 and 2 AMPK have been generated to study the specific role of 
each isoform in glucose metabolism and diabetes (Viollet, Andreelli et al. 2003). It has 
been found that 2 but not 1 AMPK knockout mice exhibited glucose intolerance and 
reduced insulin sensitivity (Viollet, Andreelli et al. 2003). Surprisingly, both mice models 
showed no specific cardiac phenotype under normal conditions. However, 2 AMPK 
deficient mice showed some cardiac phenotype under various stressful conditions as 
described above. In addition, 2 AMPK deficiency in mice resulted in a decreased 
substrate utilization by cardiac mitochondria and an inhibited respiration rate through 
complex I (Athea, Viollet et al. 2007).  
Previously, Jorgensen SB et al 2004 and Viollet B et al 2003 have demonstrated an 
upregulation of 1 isoform in the skeletal muscle of 2 AMPK knockout mice, which may 
compensate for the loss of 2 AMPK to some extent. In concurrence to these reports, a 
similar phenomenon was also observed in the skeletal muscle but not in the cardiac 
 69 
tissue of 2 AMPK knockout mice in the present study (Figure 22). Interestingly, the 
expression of both mitochondrial and nuclear-encoded complex IV was lower in both 
cardiac and skeletal muscle of 2 AMPK knockout mice compared to the wild type mice 
(Figure 23). However, the expression of both mitochondrial and nuclear-encoded 
complex I was not affected in these mice suggesting no general defect in mitochondrial 
function. In contrast, there was no change in the expression of these genes in the cardiac 
tissue of 1 AMPK knockout mice. These findings suggest that although upregulation of 
the 1 AMPK isoform in 2 AMPK knockout mice might compensate some of the 
functions of the 2 isoform, its effect on mitochondrial function seems to be unique to 2 
AMPK. Therefore, these data suggest a more profound regulatory role of 2 but not 1 
isoform in the control of mitochondrial function in the heart. This view is further 
strengthened by the study of Jørgensen et al 2004, where the authors show that the 
expression of mitochondrial cytochrome c and COX I were reduced by 20% in the 
skeletal muscle of 2 AMPK knockout mice compared to wild-type mice. 
Differences in the data obtained from H9C2 cardiomyoblasts and muscles of AMPK 
knockout mice may be related to the experimental conditions (e.g. cardiac myoblast and 
fully differentiated cardiac muscle). The basal expression of mitochondrial genes in 
muscle may not differ between wild-type mice and knockout mice, but it might be altered 
under stressful conditions. The basal reduction in mitochondrial complex IV expression 
in 2 AMPK knockout mice could just demonstrate the importance of 2 isoform in the 
regulation of basal gene expression of this particular component of the respiratory chain, 
possibly via direct phosphorylation of the relevant transcription factors regulating 
complex IV components.  
 
5.4 Adiponectin-induced AMPK activation requires the presence of 
T-cadherin in H9C2 cardiomyoblasts. 
It has previously been suggested that adipoR1 is a receptor for globular adiponectin, 
whereas adipoR2 acts as a receptor for full-length adiponectin (Yamauchi, Kamon et al. 
2002). However, knockdown of adipoR1 resulted in an abrogation of recombinant 
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full-length adiponectin-induced AMPK activation, whereas knockdown of adipoR2 
resulted in a reduction in the activity of PPAR- in liver (Yamauchi, Nio et al. 2007). 
Additionally, T-cadherin was identified as an adiponectin receptor by its ability to 
specially bind the physiological high-molecular weight adiponectin in vitro (Hug, Wang 
et al. 2004). T-cadherin is a glycosylphosphatidylinositol (GPI)-anchored molecule and 
lacks a cytoplasmic region (Ranscht and Dours-Zimmermann 1991). Recently, it has 
also been shown that T-cadherin is critical for high-molecular weight 
adiponectin-mediated cardioprotection in mice (Denzel, Scimia et al. 2010). T-cadherin 
was suggested to act as coreceptor for both adipoR1 and adipoR2 in the heart (Denzel, 
Scimia et al. 2010). 
In the present study, the knockdown of either adipoR1 or adipoR2 resulted in a 
reduction in basal AMPK phosphorylation (Figure 10), suggesting that both adipoR1 and 
adipoR2 regulate the basal activation of AMPK in H9C2 cardiomyoblasts. This is in 
accordance with a previous report demonstrating that the muscle specific adipoR1 
knockout reduces basal AMPK phosphorylation, PGC-1 expression, mitochondrial 
content and exercise capacity in the skeletal muscle (Iwabu, Yamauchi et al. 2010). 
Data on cardiac specific adipoR1 knockouts or the effect of adipoR2 knockout on basal 
AMPK activation in the skeletal or cardiac muscle are not available yet. However, in 
failing myocardium, a reduction in the basal protein expression of adipoR1, adipoR2 
and AMPK phosphorylation was observed (Khan, Kato et al. 2012). This suggests a 
possible relationship between adipoR1/2 and basal AMPK activation in the heart under 
stressful conditions. 
Adiponectin-induced AMPK phosphorylation has been shown to be abrogated by 
knockdown of adipoR1 or adipoR2 in a variety of cell types (Iwabu, Yamauchi et al. 
2010; Kim, Lee et al. 2010; Xiao-jun, Min et al. 2010). Similarly, impaired AMPK 
activation induced by recombinant full-length adiponectin was also observed in the 
skeletal muscle of ob/ob mice exhibiting decreased expression of adipoR1 and adipoR2 
(Tsuchida, Yamauchi et al. 2004). In the present study, AMPK phosphorylation by 
recombinant full-length adiponectin was not completely abolished by either adipoR1 or 
adipoR2 knockdown alone in H9C2 cardiomyoblasts (Figure 10). This may be due to 
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either partial knockdown of adipoR1/2 or compensation by the respective other adipoR 
(Figure 9). However, the compensation of the remaining adipoRs for the partial adipoR1 
loss seemed to be less effective. This may suggest that adipoR1 contributes more to the 
adiponectin-induced AMPK phosphorylation than adipoR2 and raises the question if 
other proteins/co-receptors, which mediate the adiponectin-AMPK signaling, are 
involved.  
Comparison of the expression of different adiponectin receptors in H9C2 
cardiomyoblasts and adult cardiomyocytes showed a high expression of T-cadherin in 
both cell types (Figure 8). Therefore, the role of T-cadherin in AMPK phosphorylation 
was further investigated. Unlike adipoR1 and adipoR2, T-cadherin knockdown did not 
result in a reduction in basal AMPK phosphorylation (Figure 10), suggesting that 
T-cadherin is not required for the basal AMPK activation. However, adiponectin was 
unable to induce AMPK phosphorylation in T-cadherin knockdown cells (Figure 10), 
suggesting that T-cadherin might be necessary for adiponectin binding on the cell 
surface and adiponectin-mediated AMPK activation in H9C2 cardiomyoblasts. This 
finding is in accordance to a previous report (Denzel, Scimia et al. 2010) showing that 
cardiac T-cadherin expression was dependent on adiponectin serum concentration and 
adiponectin could directly bind to T-cadherin mediating adiponectin effects in heart 
(Denzel, Scimia et al. 2010).  
However, abundant T-cadherin alone in the skeletal muscle was also not sufficient for 
many adiponectin effects, as indicated by Yamauchi et al 2007 and Iwabu et al 2010. 
They showed that in mice with a skeletal muscle-specific knockout of adipoR1, but not 
adipoR2, full-length adiponectin failed to regulate AMPK activation and muscle 
metabolism (Yamauchi, Nio et al. 2007; Iwabu, Yamauchi et al. 2010). Thus, T-cadherin 
might be a major component of the adiponectin signaling pathway and may mainly 
cooperate with adipoR1 in muscle cells. 
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5.5 Adiponectin-induced AMPK activation is mediated by both LKB1 and 
CaMKK in H9C2 cardiomyoblasts. 
LKB1 and CaMKK are two well known AMPK kinases in mammalian cells. Both of 
these two kinases regulate AMPK phosphorylation via different signaling mechanisms in 
different tissues and organs. LKB1 is known to be the most prominant AMPK kinase 
(Koh, Brandauer et al. 2008). Deletion of LKB1 in cardiomyocytes leads to an energy 
deprivation and cardiac dysfunction, which was due to complete ablation of 2 AMPK 
activity (Koh, Brandauer et al. 2008). Similarly, cardiac deficiency of LKB1 also results in 
a cardiac hypertrophy which was due to impaired AMPK and mTOR/p70S6/eEF2 
signaling (Ikeda, Sato et al. 2009). Furthermore, LKB1/2 AMPK signaling were 
reported to be important for the long-chain fatty acid uptake and utilization in 
cardiomyocytes during the contraction of heart (Habets, Coumans et al. 2009). In our 
previous study we have also demonstrated a strong correlation between LKB1 
expression and AMPK activation in human right atrial tissue (Niemann, Pan et al. 2013). 
Other studies have also demonstrated an essential role of CaMKK in the regulation of 
AMPK phosphorylation in the heart (Horie, Ono et al. 2008; Li, Zhang et al. 2011). Both 
LKB1 and CaMKK have also been shown to regulate Glut4 translocation and glucose 
uptake in cardiomyocytes and protect cardiac myocytes against ischemic injury by 
others (Horie, Ono et al. 2008). Likewise, morphine, an exogenous non-peptide opioid 
receptor agonist, ameliorates myocardial contractile dysfunction and limits infarct size 
following ischemia and reperfusion by Ca2+-CaMKKβ-dependent phosphorylation of 
AMPK (Li, Zhang et al. 2011). These studies suggest that both LKB1 and CaMKK 
mediate the effect of adiponectin on AMPK activation in the heart and in H9C2 
cardiomyoblasts. 
In accordance to these data, either LKB1 or CaMKK knockdown led to a reduction in 
basal AMPK phosphorylation in H9C2 cardiomyoblasts in the present study (Figure 12). 
The effect of LKB1 or CaMKK knockdown on basal AMPK phosphorylation (Figure 12) 
was comparable to that of adipoR1 or adipoR2 knockdown (Figure 10), suggesting the 
requirement of all these four components in the regulation of basal AMPK 
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phosphorylation in H9C2 cardiomyoblasts. Either component is indispensable in this 
regulation. 
Till now, LKB1 has been believed to regulate adiponectin-induced AMPK 
phosphorylation in most cell types (Awazawa, Ueki et al. 2009; Taliaferro-Smith, 
Nagalingam et al. 2009; Zhou, Deepa et al. 2009). We show for the first time that both 
LKB1 and CaMKK are responsible for adiponectin-induced AMPK phosphorylation in 
H9C2 cardiomyoblasts. Data of the present study show that knockdown of either LKB1 
or CaMKK abrogated the adiponectin-mediated AMPK phosphorylation in H9C2 
cardiomyoblasts (Figure 12). This effect was different from the effect of adipoR1 or 
adipoR2 knockdown on adiponectin-induced AMPK phosphorylation (Figure 10). This 
suggests a stronger dependence of adiponectin/AMPK signaling pathway on LKB1 and 
CaMKK than on adipoR1/2 in H9C2 cardiomyoblasts. 
Therefore, the present study suggests that in H9C2 cardiomyoblasts, both LKB1 and 
CaMKK act as AMPK kinases, responsible for the basal AMPK phosphorylation and 
mediating the adiponectin effects. However, further studies are needed to investigate 
whether activation of both LKB1 and CaMKK is interdependent.  
 
5.6 AMPK activation has an anti-apoptotic effect. 
Both anti-apoptotic and pro-apoptotic effects of AMPK activation have been described in 
vivo and in vitro (Shibata, Sato et al. 2005; Sasaki, Asanuma et al. 2009; Kim, Miller et 
al. 2011; Konishi, Haraguchi et al. 2011). It has been shown that adiponectin protects the 
heart from ischemia/reperfusion injury via activation of AMPK and inhibition of TNF- in 
isolated rat neonatal cardiomyocytes and fibroblasts (Shibata, Sato et al. 2005). These 
effects were reversed by an overexpression of the dominant negative form of  AMPK 
(Shibata, Sato et al. 2005). Konishi et al 2011 demonstrated that adiponectin-induced 
AMPK activation protected the mouse heart from doxorubicin-induced cardiomyopathy 
by an anti-apoptotic effect mediated via an upregulation of the anti-apoptotic gene Bcl-2 
and a downregulation of the pro-apoptotic gene Bax (Konishi, Haraguchi et al. 2011). 
The authors also suggested that AMPK-induced Bcl-2 expression interferes with 
cytochrome c release from mitochondria and suppresses apoptosis progression. 
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Similarly, metformin has been shown to attenuate oxidative stress–induced 
cardiomyocyte apoptosis in dogs via AMPK activation (Sasaki, Asanuma et al. 2009). It 
also improved the left ventricular function and survival via activation of AMPK and its 
downstream effectors eNOS and PGC-1 in a murine model of heart failure (Gundewar, 
Calvert et al. 2009). Moreover, A-769662, a direct activator of AMPK, has been reported 
recently to protect heart against ischemia/reperfusion injury through AMPK-mediated 
activation of eNOS and eEF2 in isolated mouse hearts (Kim, Miller et al. 2011). 
Contrariwise, pro-apoptotic effects of AMPK activation have also been reported. In most 
of those studies, AICAR is used as the AMPK activator. It has been shown that 
AICAR-induced AMPK activation results in apoptosis in B lymphocytes but not in T 
lymphocytes (Campas, Lopez et al. 2003). Moreover, it has been shown that 
AICAR-induced AMPK activation potentiates the doxorubicin-induced cell death and 
apoptosis in H9C2 cardiomyoblasts, which is mediated by JNK, p53 regulation and 
mTORC1 inhibition (Chen, Wu et al. 2011). However, JNK activation induced by AICAR 
has previously been shown to be linked to excitotoxic apoptosis where cells are 
damaged and killed by excessive stimulation (Borsello, Clarke et al. 2003; Chen, 
Montagnani et al. 2003). Therefore, AICAR may result in an over-activation of AMPK, 
which is then detrimental. In endothelial cells, it has been shown that 1 but not 2 
AMPK activation suppressed apoptosis via increasing NF-B activation and the 
expression of anti-apoptotic proteins Bcl-2 and Survivin (Liu, Liang et al. 2010), 
indicating an anti-apoptotic effect of 1 AMPK in endothelial cells. 
However, the specific role of the  AMPK isoforms in apoptosis prevention has not been 
investigated in H9C2 cardiomyoblasts or cardiomyocytes in detail so far. Data of the 
present study show that both physiological and pharmacological activation of AMPK 
exerts an anti-apoptotic effect in H9C2 cardiomyoblasts (Figure 27). Moreover, both 
AMPK activators not only reduced the basal ROS production but also attenuated 
H2O2-induced ROS production (data not shown) in H9C2 cardiomyoblasts suggesting 
that the anti-apoptotic effects of AMPK maybe due to a reduced ROS production.   
Interestingly, a significant reduction in cell viability (Figure 26) and a dramatic induction 
in caspase 3/7 activities (Figure 28) were observed in 2 but not in 1 knockdown H9C2 
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cardiomyoblasts in the present study. These data indicate that, in H9C2 cardiomyoblasts, 
the 2 isoform but not the 1 isoform (as shown in endothelial cells) is involved in 
anti-apoptotic effects of AMPK. 
 
5.7 AMPK deletion suppresses cell proliferation. 
Both anti-proliferative and pro-proliferative effects of AMPK activation have also been 
described. The anti-proliferative effects of AMPK may be mediated via multiple 
mechanisms including the regulation of cell cycle (Williamson, Butler et al. 2009) and 
inhibition of protein synthesis (Bolster, Crozier et al. 2002). Cell cycle regulation by 
AMPK is mediated by up-regulation of the p53/p21 axis as well as regulation of 
TSC2/mTOR pathway (Igata, Motoshima et al. 2005; Jones, Plas et al. 2005). Both 
eEF2 and mTOR signaling are involved in mediating the inhibitory effect of AMPK on 
protein synthesis. mTOR has been reported to be inhibited by AMPK activation through 
TSC2 phosphorylation, which in turn leads to an inhibition of protein synthesis (Inoki, 
Zhu et al. 2003). Phosphorylation and inhibition of eEF2 by eEF2 kinase which can be 
phosphorylated by AMPK also leads to the inhibition of protein synthesis (Chan, Soltys 
et al. 2004).  
Although the previous studies were mainly performed in cancer cells, some studies in 
non-cancer cells also showed the suppressive effect of AMPK activation on cell 
proliferation. AMPK activation induced by AICAR suppresses the proliferation of 
vascular smooth muscle cells via cell cycle regulation, which occurs through p53 
upregulation and increased expression of cyclin-dependent kinase inhibitor p21CIP 
(Igata, Motoshima et al. 2005). In vivo treatment with AICAR results in a 45% reduction in 
protein synthesis in rat skeletal muscle, accompanied by a reduced phosphorylation of 
protein kinase B, mTOR, ribosomal protein S6 kinase and eukaryotic initiation factor 
eIF4E-binding protein (Bolster, Crozier et al. 2002). 
Contrary to this, several other studies have demonstrated pro-proliferative effect of 
AMPK activation. It has been shown that AICAR-induced activation of AMPK enhances 
angiotensin II-induced proliferation in cardiac fibroblasts, but 1 AMPK deficiency 
suppresses this effect (Hattori, Akimoto et al. 2006). In the present study, a ~50% 
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reduction in cell proliferation in 2 but not in 1 AMPK knockdown H9C2 
cardiomyoblasts was observed by analysis of cell growth under microscope (Figure 24). 
The BrdU incorporation data, however, showed that knockdown of either 1 or 2 
AMPK resulted in a reduction in BrdU incorporation, which was further reduced when 
both 1 and 2 AMPK were knocked down simultaneously (Figure 25). Similar results 
were obtained in our lab in a cancer cell line, Hela cells (data not shown). These data 
indicate that both isoforms of  AMPK are required for the proliferation of both cardiac 
and cancer cell lines. The results on cell proliferation obtained by microscope or by 
BrdU-labling differed in 1 AMPK knockdown cells, showing a normal proliferation by 
microscope (Figure 24), but a significantly reduced BrdU-incorporation (Figure 25). BrdU 
is only incorporated into newly synthesized DNA of replicating cells (S phase of the cell 
cycle), which was measured for 2 hours in our experiments. It can be explained by 
different knockdown time required by 1 and 2 AMPK for affecting proliferation. 
Knockdown of 1 AMPK starts to slow down proliferation at least after 48 hours, which 
was demonstrated by a decreased DNA replication after 48 hours (Figure 25) and a 
normal cell mitosis within 48 hours (Figure 24). Meanwhile, knockdown of 2 AMPK 
starts to slow down proliferation just after 24 hours, which was demonstrated by a 
decreased DNA replication after 48 hours (but might already happen after 24 hours) 
(Figure 25) and a decreased cell mitosis after 24 hours (Figure 24). Therefore, it is 
conceivable that both isoforms of  AMPK are required for DNA synthesis in H9C2 
cardiomyoblasts. Further studies are required to investigate the details of these two 
isoforms in the regulation of the cell cycle. The present study suggests that both 1 and 
2 isoforms of AMPK contribute to the proliferation of H9C2 cardiomyoblasts.  
 
5.8 AMPK - a therapeutic target in cardiac disease. 
Studies using both genetic and pharmacological approaches have demonstrated 
important roles of AMPK in protecting the heart during ischemia/reperfusion injury as 
well as in pathological hypertrophy and heart failure. Activation of the AMPK pathway 
may therefore be a novel therapeutic strategy in treating and preventing various cardiac 
diseases.  
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The results obtained in the present study provide additional data for this protective effect 
of AMPK activation, induced either by physiological or by pharmacological activators. 
Both 1 and 2 AMPK may protect the failing heart by promoting mitochondrial 
biogenesis and improving mitochondrial function. Furthermore, the 2 isoform may 
protect the heart from injury by improving cell survival via anti-apoptotic mechanisms, 
partially mediated by a reduction in ROS production. Although the present study 
investigated only some aspects of AMPK-mediated protective effects and the signaling 
pathways involved in this process, it demonstrated that AMPK, at least in part, plays a 
role in protecting cardiac cells. A better understanding of the physiology of AMPK and 
the mechanisms of the action of its existing natural and pharmacological activators is 
needed if the modulation of AMPK activity for the treatment and prevention of 
cardiovascular diseases is intended to be used in patients. 
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6. Summary 
In the present study, the protective effects of adiponectin-AMPK signaling on 
mitochondrial biogenesis, apoptosis and cell proliferation in cardiac cells (adult 
cardiomyocytes, H9C2 cardiomyoblasts) were investigated. The role of 1 and 2 
AMPK in these processes were examined. Adiponectin was able to induce the 
phosphorylation of AMPK as well as its target ACC in all these cell types. In H9C2 
cardiomyoblasts, adiponectin-induced AMPK phosphorylation was mediated by both 
adipoR1 and adipoR2, and T-cadherin acted as co-receptor for adipoRs. Both AMPK 
kinases LKB1 and CaMKK were involved in adiponectin-induced AMPK 
phosphorylation. AMPK phosphorylation either by adiponectin or A-769662 (a 
pharmacologic agent) showed similar effects on mitochondrial gene expression. In 
H9C2 cardiomyoblasts, adiponectin increased the enzyme activities of various 
respiratory chain complexes, which was abolished by AMPK inhibition. With the help of 
three stable inducible H9C2 cell lines (control, 1 AMPK knockdown and 2 AMPK 
knockdown), it was observed that: (1) both 1 and 2 AMPK were required for the 
expression and activation of mitochondrial complex I and therefore the mitochondrial 
respiration via complex I-III respiratory chain, but not complex II-III respiratory chain; (2) 
and both 1 and 2 AMPK were required for the expression and activation of 
mitochondrial complex IV. Furthermore, AMPK activation by either adiponectin or 
A-769662 showed an anti-apoptotic effect in H9C2 cardiomyoblasts. 2 AMPK deletion 
resulted in cell apoptosis indicated by lower cell viability and rather higher activities of 
caspase3/7. Both 1 and 2 AMPK were required for the proliferation of H9C2 
cardiomyoblasts, which was demonstrated by less DNA replication in these AMPK 
knockdown cells. Data of the present study revealed protective effects of 1 and 2 
AMPK in cardiac cells, which may also suggest an important role of AMPK, as a 
potential therapeutic target, in the treatment of cardiac diseases. 
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6. Zusammenfassung 
In der vorliegenden Arbeit wurden die protektiven Effekte des 
Adiponektin-AMPK-Signalweges auf die mitochondriale Biogenese, Apoptose und 
Zellproliferation in Herzzellen (adulte Kardiomyozyten sowie H9C2 Kardiomyoblasten) 
untersucht. Dabei wurde die Rolle der 1- und 2-AMPK näher beleuchtet. In allen 
beobachteten Zelltypen induzierte Adiponektin die Phosphorylierung sowohl der AMPK, 
als auch von deren Zielenzym, der ACC. In H9C2 Kardiomyoblasten vermittelten 
adipoR1 und adipoR2 die Adiponektin-induzierte AMPK-Phosphorylierung, während 
T-Cadherin als Co-Rezeptor dieser Rezeptoren fungierte. Die AMPK-Kinasen LKB1 und 
CaMKK waren ebenfalls an der Adiponektin-induzierten AMPK-Phosphorylierung 
beteiligt. Die AMPK-Phosphorylierung durch Adiponektin zeigte den gleichen Effekt auf 
die mitochondriale Genexpression wie A-769662 (ein pharmakologisches Agens). In 
H9C2 Kardiomyoblasten steigerte Adiponektin die Enzymaktivität zahlreicher Komplexe 
der Atmungskette, was durch Inhibition der AMPK verhindert wurde. Mit Hilfe von drei 
stabil induzierbaren H9C2 Zelllinien (Kontrolle, 1-AMPK-knockdown und 
2-AMPK-knockdown) konnte gezeigt werden, dass (1) sowohl 1-, als auch 2-AMPK 
für die Expression und Aktivierung des mitochondrialen Komplex I und dadurch für die 
mitochondriale Atmung via Komplex I-III der Atmungskette, nicht jedoch via Komplex 
II-III benötigt wurden; (2) beide AMPK-Isoformen für die Expression und Aktivierung des 
mitochondrialen Komplex IV erforderlich waren. Weiterhin zeigte die AMPK-Aktivierung 
durch Adiponektin oder A-769662 einen antiapoptotischen Effekt in 
H9C2-Kardiomyoblasten. Die Deletion der 2-AMPK resultierte in gesteigerter 
Apoptose, welche durch eine geringere Zellviabilität und eine gesteigerte Aktivität der 
Caspasen 3 und 7 gezeigt wurde. Beide AMPK-Isoformen wurden für die Proliferation 
von H9C2 Kardiomyoblasten benötigt, was anhand geringerer DNA-Replikation in den 
AMPK-Knockdown-Zellen demonstriert werden konnte. Die Ergebnisse der 
vorliegenden Arbeit zeigen protektive Effekte der 1- und der 2-AMPK in kardialen 
Zellen und verdeutlichen die wichtige Rolle der AMPK als potentielles therapeutisches 
Ziel in der Behandlung kardialer Erkrankungen. 
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7. Abbreviations 
AMPK     AMP-activated protein kinase 
AdipoR     Adiponectin receptor 
ACC     Acetyl-coenzyme A-carboxylase  
acrp30     Adipocyte complement-related protein of 30 kDa 
AICAR     5-aminoimidazole-4-carboxamide ribonucleoside 
AMP / ADP / ATP  Adenosine mono- / di- / tri-phosphate 
AMPKK     AMPK Kinase 
APPL  Adaptor protein containing pleckstrin homology domain, 
 phosphotyrosine binding domain and leucine zipper motif 
APS     Ammonium persulfate 
CaMKK    Ca2+-calmodulin-dependent protein kinase kinase β 
CBS     Cystathionine-ß-synthase 
COX     Cytochrome c oxidase 
CPT1     Carnitine Palmitoyl Transferase 1 
CS      Citrate synthase 
DAPI     4‘6-diamidino-2-phenylindol 
(d)dNTP    (Di)deoxyribonucleotide triphosphate  
DEPC     Diethylpyrocarbonate  
DMSO     Dimethyl sulfoxide  
dsRNA     Double stranded RNA 
EDTA     Ethylene-diamine-tetra-acetic acid  
eEF2     Eukaryotic elongation factor-2 
eNOS     Endothelial nitric oxide synthase 
ERK     Extracellular signal regulated kinase 
ERR     Estrogen-related receptor alpha 
F-2,6-P2    Fructose-2,6- bisphosphate 
FADH     Flavin adenine dinucleotide 
G-6-PDH    Glucose-6-phosphate-dehydrogenase  
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GAPDH     Glyceraldehyde-3-phosphate-dehydrogenase 
GEF     Glut4 enhancer factor 
Glut4     Glucose transporter 4 
GS      Glycogen synthase 
HMGR     3-hydroxy-3-methylglutaryl-CoA reductase 
HRP     Horseradish peroxidise 
HSL     hormone-sensitive lipase 
LCFA     Long-chain fatty acids 
LDH     Lactate dehydrogenase 
LKB1     STK11, Serine / Threonine kinase 
LMW / MMW / HMW  Low / middle / high molecular weight 
LPL      Lipoprotein lipase 
MAPK     Mitogen-activated protein kinase 
MCD     Malonyl-CoA decarboxylase 
MLCK     Myosin light chain kinase 
MIF      Macrophage migration inhibitory factor 
mRNA     Message RNA 
mTOR     Mammalian target of rapamycin 
Tfam     Mitochondrial transcription factor A 
NADH     Nicotinamide adenine dinucleotide  
NRF     Nuclear respiratory factor  
p70S6     p70 ribosomal protein S6 
pACC     Phosphorylated form of ACC 
pAMPK     Phosphorylated form of AMPK 
PBS     Phosphate buffered saline 
PFK-2     Phosphofructokinase-2 
PGC-1     Peroxisome proliferator-activated receptor-γ coactivator-1 
PGI      Phosphoglucose-isomerase 
PI      Propidium iodide 
PPAR     Peroxisome proliferator-activated receptor alpha 
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RISC     RNA-induced silencing complex 
RNAi     RNA-interference 
ROS     Reactive oxygen species 
RXR     Retinoid X receptor 
18S rRNA    18S ribosomal RNA  
SDH     Succinate-dehydrogenase 
SDS-PAGE    Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
SEM     Standard error of the mean 
sh / siRNA    Short hairpin / small interfering RNA 
SIRT1     Silent mating type information regulator 2 homolog 1 
SOD     Superoxide dismutase 
TAK1     Transforming growth factor-β-activated kinase 1 
Taq-Polymerase   DNA-Polymerase from Thermus aquaticus 
TBS-T     Tris-buffered saline Tween-20 
TCA cycle    Tricarboxylic acid cycle 
TEMED     N,N,N´,N´-tetramethyl-ethylene diamine 
Thr, T     Threonine 
Tris      Tris-(hydroxymethyl)-aminomethan 
Trx      Thioredoxin 
TSC     Tuberous sclerosis complex  
VEGF     Vascular endothelial growth factor 
ZMP  5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl-5´-
 monophosphate 
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